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Abstract 
 
 
      Osteoporosis  is a complex skeletal disease, characterized by low bone mineral 
density (BMD) and microarchitectural deterioration of bone tissue, with a 
consequent increase in bone fragility, leading to higher susceptibility to fractures. 
Many recent studies indicated that BMD is – at least in part – genetically 
determined. However, the most common candidate genes appearing to be closely 
linked with variation in BMD and high risk to develop osteoporosis, are vitamin D 
receptor (VDR) and methylene tetrahydrofolate reductase (MTHFR) genes. The 
hypothesis that commonly occurring polymorphisms
 
in the VDR and MTHFR 
genes affect BMD has raised
 
great interest. Several studies have confirmed this 
relationship– although some are contradictory –, while others showed negative 
findings. 
      In
 
our present study, we have analyzed the Bsm-I
 
and Fok-I
 
polymorphisms in 
the VDR gene using RFLP-PCR, and the (C677T) MTHFR polymorphism using 
ARMS-PCR, in association with BMD in 344 (165 osteoporotic, 93 osteopenic, 
and 86 normal) Palestinian women in Bethlehem district. Secondly, we also 
investigated whether this association is affected by gene-gene interaction, or gene-
environmental interaction including years since menopause, height, and weight.  
 VIII 
      The results of these analysis indicate clearly the presence of  significant 
associations between the b-allele of the Bsm-I VDR gene and high BMD, as well 
as significant associations between the CT genotype of the MTHFR gene and 
decreased BMD compared to the TT genotype. On the contrary, the Fok-I VDR 
RFLP alone was a weak predictor of BMD. Interestingly, the gene-gene 
interactions, and gene-environmental interactions results indicate significant 
association between them and predicting the BMD level.  
---------------------------------------------------------------------------------------------------- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XI 
 
 
 
 هلخص
 
 
ى ي الجينية ذات التغير الطبيعي في سلسلة الحاهض النىوي الرايبىزي هنسوع الأكسجاتالعلام
بيي النساء الفلسطينيات الوصابات بهشاشة العظام  )RDV& RFHTM(في الجينيي  )AND(
 والسليوات في هحافظة بيث لحن
 
َقص فٙ كزبفت انؼظى : ْشبشت انؼظبو ْٕ يشض ٚصبة بّ انٓٛكم انؼظًٙ نلإَسبٌ، يٍ خصبئصّ   
.  ٔكخهخّ ٔببنخبنٙ صٚبدة انٓشبشت ٔانهَٕٛت فٙ انؼظى ٔصٚبدة احخًبل كسشْب َخٛجت أ٘ حبدد بسٛػ
د يٍ انذساسبث انحذٚزت إنٗ ٔجٕد ٘ػذالأشبسث حٛذ : ُْبك ػذة ػٕايم يسببت فٙ حذٔد ْزا انًشض   
ٔيٍ أْى انجُٛبث انخٙ ربج أٌ نٓب ػلاقت .  احخًبل حذٔد انًشض حسبْى فٙ صٚبدةػٕايم جُٛٛت ٔسارٛت
حٛذ ٔجذ أٌ ُْبك حغٛش غبٛؼٙ فٙ سهسهت انحبيط انُٕٔ٘ . )RDV & RFHTM(بٓشبشت انؼظبو ْٙ 
فٙ كم يٍ ْزٍٚ انجٍُٛٛ، ٚؤد٘ إنٙ إٚجبد صبغبث ٔسارٛت يخعبدة انصفبث  )AND(يُضٔع الأكسجٍٛ 
أربخج بؼط انذساسبث انحذٚزت أٌ ٔجٕد ْزِ انصبغبث انٕسارٛت نّ ػلاقت بكزبفت انؼظى ػُذ  ٔقذ ).selella(
. بؼعٓب اٜخش أَكش ْزِ انؼلاقت، أٔ أٔجذ ػلاقت ػكسٛتبًُٛب انسٛذاث، 
 انُسبء فٙ حٕصٚغ ْزِ انصبغبث انٕسارٛت يخعبدة انصفبث بحذانٓذف يٍ ْزِ انذساست ْٕ    اٌ 
انفهسطُٛٛبث انسهًٛبث ٔانًصبببث بٓشبشت انؼظبو فٙ يحبفظت بٛج نحى، رى يؼشفت إٌ كبٌ ُْبك ػلاقت بٍٛ 
ٔكزبفت انؼظى، ببلإظبفت إنٗ يؼشفت حأرٛش اسحببغ ْزِ انصبغبث انًخخهفت نهجٍُٛٛ يؼب  )selella(ْزِ انصفبث 
.   ٔانؼًش بؼذ اَقطبع انذٔسة،بكزبفت انؼظى، ٔاسحببغٓب ببنؼٕايم انبٛئٛت الأخشٖ يزم انٕصٌ، انطٕل
ػبيم نم )1-koF + 1-msB: ( نقذ حى ححهٛم رلارت يٍ ْزِ انخغٛشاث انطبٛؼٛت نسهسهت انحبيط انُٕٔ٘   
 :سهسهت انىببسخخذاو حقُٛت حفبػلاث انبهًشة )RFHTM (ػبيم انٕسارٙنم ) )T-C(، ٔ)RDV (انٕسارٙ
 سٛذة ٤٤٣ ػُذ RFHTM ػبيم انٕسارٙنم ) )RCP-SMRA( ٔRDV ػبيم انٕسارٙنم ) )RCP-PLFR(
. يٍ يُبغق يحبفظت بٛج نحى ) سهًٛت٩٧۱+ يصببت ٥٦۱ (
 فٙ ححهٛم SSPSبؼذ يؼشفت كٛفٛت حٕصٚغ ْزِ انصبغبث ػهٗ انؼُٛت انًذسٔست، حى اسخخذاو بشَبيج    ٔ
 يُبغق انؼًٕد انفقش٘،   فٙ - انُخبئج نًؼشفت إرا كبٌ ُْبك ػلاقت بٍٛ أ٘ يٍ ْزِ انصبغبث ٔكزبفت انؼظى
.  ٔيذٖ حأرٛش انؼٕايم انبٛئٛت الأخشٖ ػهٗ ْزِ انؼلاقت؛ - انحٕض، ٔأػهٗ انفخزٔ
 X 
 ْزِ انؼلاقت نٛسج أٌ. َخٛجت نٓزِ انذساست، ٔجذ أٌ ُْبك ػلاقت بٍٛ ْزِ انصبغبث ٔيؼذل كزبفت انؼظى   
 حكًٍ أًْٛت ْزِ  ٔ.بسٛطت، بم يشحبطت بؼٕايم أخشٖ يزم انطٕل، انٕصٌ، ٔانؼًش بؼذ اَقطبع انذٔسة
 إٌ كبٌ نذٚٓب قببهٛت نًؼشفتانذساست فٙ أٌ أ٘ فخبة، إرا قبيج بٕقج يبكش بؼًم فحص ححهٛهٙ نٓزِ انجُٛبث 
ٔببنخبنٙ حأخز احخٛبغبحٓب نهٕقبٚت يٍ ْزا انًشض قبم حذٔرّ، أيلا فٙ . ػبنٛت نحذٔد ْشبشت ػظبو فًٛب بؼذ
 .انخخفٛف يٍ اَخشبس ْزا انًشض بٍٛ انُسبء انفهسطُٛٛبث، نًب نّ يٍ حأرٛشاث سهبٛت ػهٗ انصحت انؼبيت
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 1 
Chapter 1 
Introduction 
 
 
1.1. What is osteoporosis? 
 
1.1.1. Definition: 
   Osteoporosis (or porous bones) is a complex systemic multifactorial skeletal 
disease, characterized by low bone mass and microarchitectural deterioration of 
bone tissue, with a consequent increase in bone fragility, leading to a higher 
susceptibility to fractures.( Levi etal.2002 , National Institutes of Health,2000, 
Maria,2001). 
   Osteoporosis was only officially defined as a disease in 1994 – while now it is 
acknowledged as a high priority health concern  . In 1994 , the World Health 
Organization (WHO) produced a definition of osteoporosis based on low Bone 
Mineral Density (BMD), as shown in figure 1.1. , as a value of BMD  2.5 SD or 
more below the mean value for young adults (i.e. a T score of less than -2.5 ). 
Severe osteoporosis was also defined by a T score below -2.5 in addition to one or 
more fractures. Individuals with T score between -1.0 and -2.5 were defined as 
having osteopenia. Consequently, for example, using standardized bone density 
measurements of the total hip, normal bone has greater than 833mg/cm²,osteopenia 
is between 833 and 648 mg/cm²,osteoporosisis is lower than 648mg/cm², while 
severe osteoporosis is established in association with fragility fractures. 
 2 
 
These definitions are very important because, in additional to their use in medical 
practice, they are  related to thresholds for therapeutic intervention, since entry to 
drug trials is usually based on these values. (Health topics,2005 , Russell,2003 , All 
about bones,2001). 
 
 
  WHO, Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis, 1998.
T-Score
World Health Organization (WHO) 
Osteoporosis Guidelines
  
  ©2004 J. Wexler                                            (All About Bones ,2001) 
 
Figure 1.1: 
WHO, Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis  
 
 
1.1.2. Pathogenesis: 
   The human  body contains over 200 bones. All  contain a mix of both cortical 
(the outer compact bone, representing 75% of the bone in the body, and is found in  
high percentage in the long shafts of  bones in our forearms and legs (i.e. the 
femoral neck)) and trabecular bone (the inner cancellous spongy bone , 
representing the remaining 25%, found in  high percentage  in the vertebrae, pelvic 
 3 
bones, and the ends of the long bones of the arms and legs) – see figure 1.2 . 
Therefore, the proportioned mix defines the strength of each bone (Brown,2000 , 
Nelson & Wernick,2000 , Health topics,2004 ,  McCarthy& Frassica,1998), while 
the growth of the bony skeleton determines the size and proportions of the body 
(Martini etal.2001). 
 
 
 
                                                                                                                        Biology II homepage 
 
Figure 1.2: Bone macroscopic structure 
 
    Like all living tissue, bones constantly repair and renew themselves in a process  
called bone remodeling . The purpose of remodeling is to allow the bone to adapt 
to changes in distribution of mechanical stress and to repair microdamage  which 
can occur in response to repeated loading (Russel,2003).Bone cells that are 
responsible for demolition are the osteoclasts. These cells secrete an acid that 
dissolves old bone martix, resulting in calcium and other minerals' release from the 
 4 
dissolved bone into the blood stream. Therefore, when the body needs calcium, it 
signals the osteoclasts to dissolve bone. Most of this material is recycled later in 
the remodeling process, but some is used to perform other functions in the body. 
   As shown in figure 1.3, the remodeling process begins when osteoclasts dissolve 
enough bone to create a tiny cavity, and die . In the second stage of remodeling, the 
osteoblasts (bone cells responsible for rebuilding bones) line the cavity with 
collagen (soft, sticky substance that forms the framework for bone), then they draw 
calcium and other minerals from the blood, forming crystals on the collagen. After 
that, the collagen and minerals harden into bone tissue. As the osteoblasts finish 
their work, they transform into mature bone cells (osteocytes) and become part of 
the new bone. These cells stay alive but are no longer active. At the end of the 
remodeling cycle, the cavity is refilled with new bone (Nelson &Wernick,2000): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3:The remodeling process  
 
© 2004 J. Wexler
Bone Remodeling Cycle
Bone lining cells
Bone
Osteoclasts
Resorption by
osteoclasts
Osteoblasts
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 In  normal healthy adults, a complete remodeling cycle lasts approximately 4 
months ,while, in individuals with osteoporosis ,a complete cycle may last 2 years 
(Lawson,2001).Only about 5 to 20% of the bone surface undergoes remodeling at 
any given time, the rest remain in a quiescent phase. In a healthy person, 5-10% of 
bone substance is replaced annually (Roche Facets,2005).  
Under normal conditions , the amount of bone made corresponds very closely to 
the amount removed , so that, in any remodeling cycle , the total amount of bone 
tends to remain constant. In osteoporosis, and as a result of different factors, net 
bone loss results from an imbalance between the two components of the bone 
renewal process ( i.e. bone resorption and bone formation). This is the 
fundamental basis of osteoporosis. More specifically, the numbers of bone 
remodeling sites increase, the extent of resorption may be greater, and the amount 
of bone replaced is smaller (Russel , 2003). Since the trabecular bones break down 
and rebuild faster than the cortical portion, they are more vulnerable to the effects 
of osteoporosis. Consequently, hip, spine, and wrist (having high percentage of 
trabecular bones) are the most common to break due to osteoporosis (Osteoporosis 
Dictionary-Miacalin,2005). The term "microarchitectural deterioration" refers to 
the thinning of the trabeculae and the loss of intertrabecular connections in bone, 
however, the incomplete replacement of osteons in cortical bone creates tunnels 
(see figure 1.4). These changes in bone mass and structure, reduce the overall 
 6 
strength of the bone and make it prone to fracture (National Institutes of 
Health,2000 , Russel,2003). 
 
A. 
 NORMAL  OSTEOPENIA  OSTEOPOROSIS  
SEVERE  
OSTEOPOROSIS  
Cortical 
bone  
    
Trabecular 
bone  
    
                                                                                                                               (All about bones,2001) 
  
B. 
 
 
  
 
                                                                                                                 (Lexi-comp Inc. ,2003) 
Figure 1.4: Effect of osteoporosis on bones 
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1.1.3. Classification: 
  There are two main types of osteoporosis: 
1. Primary osteoporosis:  occurring spontaneously, and has three subtypes: 
a -Type I ( postmenopausal) osteoporosis: caused by a lack of estrogen, the main 
female hormone, which helps to regulate the incorporation of calcium in women 
bone .                                                                                                                   
b-Type II (Senile) osteoporosis : probably results from an age-related calcium 
deficiency or a vitamin D deficiency. Senile means the condition occurs only in 
older people. It usually affects people older than 70 years and is twice as common 
in women as in men. Most older women with osteoporosis have a combination of 
postmenopausal and senile osteoporosis. 
c- Type III (Idiopathic) osteoporosis : is a rare type of osteoporosis; the word 
idiopathic simply means that the cause is unknown. This type of osteoporosis 
occurs in children and young adults who have normal hormone levels, normal 
vitamin levels, and no obvious reason to have weak bones. 
2. Secondary osteoporosis:  Is caused by another disease ( as chronic kidney 
failure and hormonal disorders (especially Cushing's disease, hyperthyroidism, 
hyperparathyroidism, , hypogonadism, and diabetes mellitus)) or by drugs ( as 
corticosteroids, barbiturates, and anticonvulsants). (Beers et al, 2003, 2004). 
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1.1.4. Symptoms & diagnosis: 
   At first, osteoporosis produces no symptoms because bone density loss occurs 
very gradually. Some people never develop symptoms. Eventually, however, 
bone density may decrease enough for bones to collapse or fracture, producing 
severe sudden pain or gradually developing aching bone pain and deformities 
(Beers etal.2003,2004). The earliest symptom of osteoporosis is often an episode 
of acute back pain caused by a pathologic vertebral compression fracture, or an 
episode of groin or thigh pain caused by a pathologic hip fracture (Glaser & 
Kaplan, 1997). 
   A doctor may suspect osteoporosis in anyone, especially older woman, who 
breaks a bone with little or no force. Bone mineral density testing can be used to 
detect or confirm suspected osteoporosis, even before a fracture occurs. A number 
of rapid screening techniques are available to measure bone density at the wrist or 
the heel; however, the most useful test is the Dual-Energy X-ray Absorptiometry 
(DEXA) , system that uses two x-ray energies to measure bone density with a low 
patient exposure and a fast scan time. DEXA measures  bone mineral density in 
two dimensions only. It is calculated by dividing the mineral content of the site of 
bone being assessed by the area of bone and is represented by the units of g/cm
2
.  
Bone density is measured at the sites where major fractures are likely to occur: the 
spine and hip. This test  is painless and can be performed in about 5 to 15 minutes. 
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It is useful for people at high risk of developing osteoporosis and for those in 
whom the diagnosis is uncertain. It is also useful for monitoring the response to 
treatment. (Beers etal.2003,2004, Cummings etal.2002). 
 
1.1.5. Epidemiology: 
  Osteoporosis is a major public health problem, occurring in every population
 
and 
geographic area studied (Klotzbuecher, 2000)
 
. In the next 60 years, it is estimated 
that the number of osteoporotic fractures will quadruple worldwide (Dubey, 1998). 
Unless decisive steps are taken now to prevent the occurrence of osteoporosis, a 
serious global epidemic appears inevitable. (Riggs & Melton III, 1995a). 
 
1.1.6. Risk Factors: 
   Many people are not aware of the risk
 
 factors and the consequences of 
osteoporosis (Klotzbuecher,2000).
 
Given that there are no symptoms before 
fracture,
 
it is important that physicians and patients recognize
 
the following risk 
factors:-                                                                                                          
a)Gender and Age: 
   Before puberty, there is no consistent gender-related differences in bone mass at 
any skeletal site (Glastre etal.1990, Bonjour etal.1991,Geusens etal.1991).This 
similarity in bone mass between males and females is maintained until the onset of 
pubertal maturation (Gilsanz etal.1991),where girls exceed boys by 10-15%, while 
boys increase during and after puberty(Aloia,1993). 
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   The graph shown below , in figure 1.5, demonstrates the changes in bone mass  
throughout an individual's lifetime (Wasnich etal.1989).  Peak bone mass is 
achieved in the mid-to-late twenties. At about 35 years old, an imbalance in bone 
turnover leads to the beginning of a gradual loss of bone (approximately 0.5 to 1 
percent per year) in both men and women.With the onset of menopause in females, 
bone loss accelerates dramatically (especially trabecular bone) as a result of 
estrogen deficiency (Gambert etal.1995). In the menopausal and immediate 
postmenopausal years, approximately 2 to 4 percent of bone is lost per year 
(Meier,1990). The reason for this increased rate of loss is not well-elucidated, but 
it may be due to changes in homeostasis or hormonal modulation of bone turnover 
(Birge,1993). There is no corresponding acceleration in bone loss seen in men. 
However, testicular function does decline somewhat with age and may contribute 
to age-related bone loss in males. After age 55 to 60, bone loss again slows to 
premenopausal rates. 
 
 
Figure 1.5: Bone Mass Changes with age  
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   The reasons for age-related bone loss are complex and poorly understood and are  
influenced by gonadal hormone status, calcium intake and bioavailability, vitamin 
D status, physical activity, and hormones such as parathyroid hormone, 
corticosteroids, thyroid hormone, growth hormone, and calcitonin (Meier,1990). 
b) Low body weight (or having small thin body frame): This may be due to the 
fact that thin women usually have lower body fat than do heavier women, so their 
estrogen levels are lower , because Fat tissue activates certain forms of estrogen 
(Beers etal.2033,2004).                                                                                              
c) Family history of osteoporosis: The genetics of osteoporosis is discussed in the 
next section.                                                                                                                                                                                                                                            
d) A history of any prior fracture (Klotzbuecher,2000)                                                      
e) Prolonged use of medicines like steroids, antiacids,& anticonvulsants                                                                           
f) Caucasian or Asian race                                                                                                            
g) Early menopause                                                                                                                             
h) Inactive lifestyle, smoking, excessive alcohol intake, caffeine intake                                       
i) Low calcium and vitamin D diet, high in salt and protein                                               
j) Low testosterone levels in men                                                                             
(Audran,2004 , Bunker,1994 , Balbona,2000, Frederic,1997)  
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1.2.Genetics of osteoporosis: 
   The genetics of osteoporosis represents one of the most active areas of research 
in bone biology (Liu etal,2003). Given the complex biology of the skeleton, it is 
likely that bone mass is under the control of a large number of genes, many of 
which exert relatively small effects on BMD and few of which contribute 
substantially to the variation in this trait. It is also likely that complex gene - 
environment interactions exist (Brandi etal.2001). Indeed, Interactions among 
genetic, hormonal and lifestyle factors are complex and in general poorly 
determined (Raya,2004). 
1.2.1. What is the evidence for genetic contribution to osteoporosis? 
    It has been shown that daughters of osteoporotic women have low BMD 
(Seeman etal.1989). A study comparing peak bone mass at both the lumbar spine 
and femoral neck in young adult daughters from peri- and early postmenopausal 
women with decreased BMD and in daughters of women with normal BMD 
showed a decreased BMD among the former group (Barthe etal.1998).                                                                                                                            
In order to investigate the proportion of the BMD variance across the population 
explained by genetic factors, which is known as the heritability (Kelly etal. 1995), 
mainly two human models have been used: Parent-offspring (family) model, and 
twin model. In the twin model, correlations for BMD are compared between 
monozygotic (MZ) twins (sharing 100% of their genes) and dizygotic (DZ) twins,  
(having 50% of their genes in common). Stronger correlation coefficients among 
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adult MZ as compared with DZ twins are indicative of the genetic influence on 
peak bone mass (Rizzoli etal.2001). Indeed, studies in twins and families indicate 
that genetic factors play an important role in the regulation of BMD and other 
determinants of osteoporotic fracture risk. For example, the heritability of BMD 
has been estimated to lie between 50% and 85% in twin studies, with the strongest 
effect in the axial skeleton (Smith etal.1973, Pocock etal.1987, Christian etal.1989, 
Slemenda etal. 1991, Flicker etal.1995). Family-based studies also yielded strong 
heritability estimates for BMD (Gueguen etal.1995), with effects that are maximal 
in young adults and persist even after adjusting for lifestyle factors that are known 
to regulate BMD (Krall & Dawson-Hughes 1993).  
    To date, among the genetic strategies commonly employed for the dissection of 
complex traits, the analysis of the genetic determinants of BMD largely relied on 
association studies, in which a polymorphism in a candidate gene is analyzed in 
untreated affected and unaffected individuals from a given population ( Brandi et 
al, 2001). 
 
1.2.2.How is Osteoporosis Inherited? 
   Osteoporosis is a complex disease, thought to be mediated by an interaction 
between environmental factors and several different genes that individually have 
modest effects on BMD and other aspects of fracture risk (Gueguen etal. 1995). In 
rare instances, however, osteoporosis is inherited in a simple Mendelian manner. 
Examples of this include osteogenesis imperfecta (Rowe,1991), and osteoporosis 
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associated with inactivating mutations in the aromatase gene (Morishima 
etal.1995) and estrogen receptor α gene (Smith etal. 1994). 
                                                                                                                                                 
1.2.3. Why Define the Genes in Osteoporosis?                                                                                              
TheThe proposed benefits of defining the genes causing osteoporosis are: (1) the 
ability to identify those who are at risk and (2) an understanding of the disease 
pathophysiology, which will facilitate the identification of novel therapeutic or 
preventative targets. Whether genetic tests are actually going to be of value in the 
prediction of those who are at risk of developing osteoporosis is quite uncertain. In 
theory, if all of the genes that cause the disease can be identified, and their 
interaction with each other and with non-genetic factors understood, then 
heritability figures from twin studies and family studies suggest that this 
information will be useful in predicting those who are at risk (Matthew,1999). 
 
1.2.4. Candidate Genes for Osteoporosis: 
    The genetic study of osteoporosis has been based largely on research into 
candidate genes relevant to bone metabolism (Liu,,2003)(see table 1.1). 
However, the most common candidate genes appearing to be closely linked with 
variation in BMD and with high risk to develop osteoporosis, are the vitamin D 
receptor (VDR) and the methylene tetrahydrofolate reductase (MTHFR) genes 
discussed in the following two sections. 
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Table 1.1: Major candidate genes showing association to bone mass variation 
 
 
Reference Chromosome 
location 
Protein Candid-
ate gene 
Biological 
classification 
Morrision et al. 1994 
Sano et al. 1995 
Ogawa et al. 2000 
Miyao et al. 2000a 
Masi et al. 1998 
Hosoi et al. 1999 
Minagawa et al. 2002 
 
Masi et al. 2001 
Huizenga et al. 1998 
Tsukamoto etal.2000a 
Sowers et al. 1999 
12q12-14 
6q25 
14q22-24 
11p15 
7q21 
11p15 
3p22-21 
 
15q21 
5q31 
3q13-21 
Xq11-12 
Vitamin D receptors 
Estrogen receptor- 
Estrogen receptor- 
Calcitonin 
Calcitonin receptor 
Parathyroid hormone 
Parathyroid hormone 
receptor 1 
Aromatase 
Glucocorticoid receptor 
Calcium-sensing receptor 
Androgen receptor 
VDR 
ER- 
ER- 
CT 
CTR 
PTH 
PTHR1 
 
CYP19 
GCCR 
CaSR 
AR 
Calciotropic hormones 
and receptors 
Langdahl et al. 1997 
 
Murray et al. 1997 
Miyao et al. 1998 
Keen et al. 1998 
 
Arko et al. 2002 
Fontova et al. 2002 
Spotila et al. 2000 
19q13 
 
7p21 
12q22-24 
2q14 
 
8q24 
6p21 
1p36 
Transforming growth 
factor- 1 
Interleukin-6 
Insulin-like growth factor I 
Interleukin-1 receptor 
antagonist 
Osteoprotegerin 
Tumor necrosis factor- 
Tumor necrosis factor 
receptor 2 
TGF- 1 
 
IL-6 
IGF-1 
IL-1ra 
 
OPG 
TNF- 
TNFR2 
Cytokines, growth 
factors and receptors 
Grant et al. 1996 
Suuriniemi et al. 2002 
Dohi et al. 1998 
Tsukamoto etal.2000b 
Dickson et al. 1994 
17q21-22 
7q22 
1q25-31 
12p13-12 
3q27 
Collagen type I 1 
Collagen type I 2 
Osteocalcin 
Matrix Gla protein 
-2-HS-glycoprotein 
COLIA1 
COLIA2 
BGP 
MGP 
AHSG 
Bone matrix proteins 
Shiraki et al. 1997 
Miyao et al. 2000b 
 
Urano et al. 2000 
 
 
Tsuji et al. 1998 
 
Ogawa et al. 1999 
 
Albegha et al. 2002 
Vaughan et al. 2002 
 
Kawano et al. 2002 
 
Ogata et al. 2001 
19q13 
1p36 
 
11p15 
 
 
6p21 
 
3p25 
 
11q13 
6p21 
 
13q12 
 
8p12-11 
Apolipoprotein E 
Methylenetetrahydrofolate 
reductase 
Cyclin-dependent kinase 
inhibitor 1c 
 
Major histocompatibility 
complex, class I, A 
Peroxisome proliferator-
activeated receptor- 
Fos-related antigen-1 
Runt-related transcription 
factor-2 
Klotho protein 
 
Werner helicase 
ApoE 
MTHFR 
 
P57(KIP
2) 
 
HLA-A 
 
PPAR- 
 
FRA-1 
RUNX-2 
 
Klotho 
gene 
WRN 
(Werner 
syndrom
e gene) 
Miscellaneous 
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1.3. Vitamin D &Vitamin D Receptor (VDR) : 
   The steroid hormone vitamin D, its receptor(VDR), and the metabolizing 
enzymes involved in the formation of the biologically active form of the hormone, 
together are major players in the vitamin D endocrine system. This system plays 
an important role in skeletal metabolism. It also seems to play an important role in 
other metabolic pathways such as those involved in osteoarthritis, the immune 
response and cancer (Haussler etal.1998).                              Figure1.6:Vitamin D                 
   *The term vitamin D actually refers to a group of 
steroid molecules.Vitamin D3, also known as 
cholecalciferol, is generated in the skin of animals when 
light energy is absorbed by a precursor molecule 7-
dehydrocholesterol.The plant form of vitamin D is called 
vitamin D2 or ergosterol.Vitamin D (as either D3 or D2) 
does not have significant biological activity. Rather, it 
must be metabolized within the body to the hormonally-
active form.This transformation occurs in two steps, as 
seen in figure 6:                                                                   
1.Within the liver, cholecalciferol is hydroxylated to 25-
hydroxycholecalciferol by the enzyme 25-hydroxylase.                                                                     
2.Within the kidney, 25-vitamin D serves as a substrate 
for 1-α-hydroxylase, yielding1,25-
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dihydroxycholecalciferol , the biologically active form of vitamin D. Each of the 
forms of vitamin D is hydrophobic and is transported in blood bound primarily to 
vitamin D binding protein(DBP) (85-88%) and albumin (12-15%) (Colorado 
S.U.2001, Bikle, 2004). However, the hormonal activities of 1,25-(OH)2D3 are 
mediated through its intracellular receptor-the vitamin D receptor (VDR) 
(DeLuca&Schnoes,1983).Vitamin D receptor binds several forms of 
cholecalciferol. Its affinity for 1,25-dihydroxycholecalciferol is roughly 1000 times 
that for 25-hydroxycholecalciferol, which explains their relative biological 
potencies (Colorado S.U.,2001).  
1.3.1.Physiological Effects of Vitamin D: 
   Vitamin D is well known as a hormone involved in mineral metabolism and bone 
growth. It promotes the differentiation of osteoblasts and regulates the production 
of proteins such as collagen, alkaline phosphatase, and osteocalcin thought to be 
important in bone formation. It also induces RANKL, a membrane bound protein 
in osteoblasts which enables osteoblasts to stimulate the formation and activity of 
osteoclasts. Thus, vitamin D regulates both bone formation and bone resorption. 
(Colorado S.U.2001, Bikle,2004).                                                                                                                                    
ItsHowever, the principle function of vitamin D is to maintain intracellular 
and extracellular calcium concentrations within a physiologically acceptable 
range, through the action on regulating calcium and phosphorus metabolism in the 
intestine and bone (in concert with parathyroid hormone and calcitonin) (figure 
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1.7). Actually, in the absence of vitamin D, dietary calcium is not absorbed at all 
efficiently.  
 
FIG. 1.7: A representation of the classic physiological actions of vitamin D: The hormonal form of vitamin D 
functions in the intestine, bone, and the distal renal tubule to mobilize calcium. In the case of the intestine, 1,25-
(OH)2Da serves to mobilize phosphorus into the plasma. Saturating levels of calcium and phosphorus support 
mineralization in the skeleton and neuromuscular junction activity (Colorado S.U.2003, Litwack,1994) 
 
   Vitamin D stimulates the expression of a number of proteins involved in 
transporting calcium from the lumen of the intestine, across the epithelial cells and 
into blood. The best-studied of these calcium transporters is calbindin, an 
intracellular protein that ferries calcium across the intestinal epithelial cell.                                                        
Thus, the crutial effect of vitamin D on bone is to provide the proper balance of 
calcium and phosphorus to support mineralization (Colorado S.U.2001&2003, 
Scientific Committee on Food,2002). 
1.3.2. Vitamin D Receptor (VDR): 
             The main mechanism of action of vitamin D is the interaction of 1,25(OH)2D 
with the nuclear vitamin D hormone receptor (Brown&Duncan, 1999).VDR was 
discovered in 1969 (Haussler&Norman,1969), and was eventually cloned and 
sequenced in 1987 (McDonnell etal.1987, Baker etal,1988). It is a protein of 
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approximately 50-60kDa depending on species. Figure 1.8 explains the basic 
structure of VDR (Daniel, 2004, Rachez et al. 2000): 
 
 
 
  
 
 
 
Figure 1.8. Model of the vitamin D receptor (VDR): The VDR is unusual 
in that its N- terminal region is short relative to other steroid nuclear  
hormone receptors. This region is followed by two zinc fingers which 
constitute the principal DNA binding domain(the most conserved 
domain in VDR among the nuclear receptors in general). Nuclear 
localization signals (NLS) are found within and just C-terminal to the 
DNA binding domain. The ligand binding domain (where vitamin D 
binds)makes up the bulk of the C-terminal half of the molecule, with the 
major activation domain (AF2)comprising the most C-terminal region. 
The AF2 domain is largely responsible for binding to co-activators . 
Regions on the second zinc finger and within the ligand binding domain 
facilitate heterodimerization with the retinoid X receptor (RXR),while 
the proximal (N-terminal) zinc finger confers specificity for DNA binding 
to the vitamin D response elements (VDREs) , as seen later. 
 
 
 
The VDR is widely distributed in most , if not all the cells in the body (Colorado 
S.U.2001). Actually, it is a transcription factor, mediating the effects of vitamin D 
on gene expression. The mechanism by which  the vitamin D hormone enter a cell 
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and regulate DNA transcription , is summarized in the next figure below 
(Bikle,2004): 
 
 
Figure 1.9: 1,25(OH)2D-initiated gene transcription: 
1,25(OH)2D enters the target cell and binds to its receptor, 
VDR. The VDR then heterodimerizes with the retinoid X 
receptor (RXR). This increases the affinity of the 
VDR/RXR complex for the vitamin D response element 
(VDRE), a specific sequence of nucleotides in the 
promoter region of the vitamin D responsive gene. 
Binding of the VDR/RXR complex to the VDRE attracts a 
complex of proteins termed coactivators to the VDR/RXR 
complex. The coactivator complex spans the gap between 
the VDRE and RNA polymerase II and other proteins in 
the initiation complex centered at or around the TATA 
box (or other transcription regulatory elements). 
Transcription of the gene is initiated to produce the 
corresponding mRNA, which leaves the nucleus to be 
translated to the corresponding protein. 
 
 
1.3.3 The VDR Gene: 
   The gene encoding the VDR was the first candidate gene to be studied in 
osteoporosis. It actually initiated  the osteoporosis' molecular genetics, chosen on 
the basis that it acts as an important regulator of calcium metabolism and bone cell 
function (Ralston,2003 , Uitterlinden,2002). The hVDR gene is located on the "q" 
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arm of human chromosome 12 (figure 1.10) , precisely at chromosome 12cen-
q12(Taymans,1999). 
Figure 1.10:Human Chromosome 12 (Warranty & Disclaimer , 2001-2005) 
                        
 The hVDR gene is approximately 100kb long and is made up of 14 exons together 
with intervening introns. As illustrated in figure 1.11, three exons (1A,1B and 1C) 
are found in the 5`non-coding sequence . Another 3 exons (1d,1e,1f) were 
discovered later (Uitterlinden etal,2004)) and 8 exons (II – IX) encode for the 
structural portion of the product. As in any other gene, different exons encode for 
different protein domains.The 3` boundaries of the exons that code for the two zinc 
fingers are highly conserved within the nuclear receptor family of genes (each of 
the two zinc fingers
 
is encoded by separate exons (II and III),as in other nuclear 
receptor genes). An intron segment found in the 3` of exon 1c shows retinoic acid 
responsivity to induce transcription, while its GC- rich promoter (which doesn't 
contain a TATA box) contains binding sites for transcriptional factors .The 
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presence of a polymorphic sequence in
 
exon II determines the presence or absence 
of
 
an alternative translation start site (see discussion of
 
FokI
 
polymorphism below).
 
A unique feature of the hVDR gene is
 
the presence of an additional exon (V) that
 
is 
not found in other nuclear receptor genes
 
;
 
it resides near the center of the gene
 
and 
encodes residues 155 194
 
in hVDR. This region of the VDR protein
 
is more 
expansive than the corresponding segment in
 
other nuclear receptors (Miyamato 
etal.1997/Faraco, 1989/Laudet,1991/Haussler etal,1998/Uitterlinden etal,2004/ 
Crofts etal.1998).
 
Figure 1.11: Human VDR Gene (Haussler etal,1998) 
 
 
1.3.4. Polymorphisms In The VDR Gene: 
   One
 
of the most intriguing, yet controversial, areas of
  
bone-related genetic 
research in the past few years
 
has been the discovery of common polymorphisms in
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the hVDR gene and their potential relationship to
 
bone mineral density (BMD) and 
the pathophysiology of
 
osteoporosis (Haussler etal,1998). In figure 1.12, and table 
2, a number of the currently known VDR polymorphisms are depicted. However, 
apart from those polymorphisms, a number of novel polymorphisms were found in 
the promoter areas including in and around exons 1f-1c, in and around exons 2-
9,and in the 3.2 kb 3′ untranslated region(UTR). Actually, 63 polymorphisms 
across 22 kb of sequences were discovered in the VDR gene (Uitterlinden, 2004). 
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Fig. 1.12. Position of known polymorphisms in the exon–intron structure of the VDR gene.                  
(*) indicates that these polymorphisms are in the coding sequence. (Uitterlinden etal,2004) 
 
  
Table 1.2: Major VDR gene Polymorphisms 
 
 
References Nucleotide 
Varient 
Amino acid 
   change 
Codon Location Polymorphism 
*Arai et al. 
2001 
*Uitterlin-
den et al. 
2004 
G/A _ _ 1e promoter: 
binding site for an 
intestinal-specific 
transcription factor 
 
CdX2 
Arai et al. 
1997 
C/T Yields 3-aa 
shorter 
protein 
ATG 
Codon 1 
(start 
codon) 
 
Exon 2 
 
FokI 
(Alleles F/f) 
Morrison 
et al. 1992 
A/G _ _ Intron 8 
(between exon 8+9) 
BsmI 
(Alleles B/b) 
Ye et al. 
2000 
G/A _ _ Intron 8 
(between exon 8+9) 
Tru 9I 
Morrison 
et al. 1992 
G/A _ _ Intron 8 
(between exon 8+9) 
Eco RV 
Faraco et 
al. 1989 
G/T _ _ Intron 8 
(between exon 8+9) 
ApaI 
(Alleles A/a) 
Morrison 
et al. 1994 
T/C Silent 
mutation 
Codon 
352 
Exon 9 TaqI 
(Alleles T/t) 
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As noticed , the only known protein polymorphism in the VDR gene is the FokI 
polymorphism (Utterlinden,2004): It is a thymine/cytosine (T/C)  transition 
(changing ATG to ACG) at the first initiation codon (ATG) located in exon 2 of 
the VDR gene. Normally, the VDR gene has two potential translation initiation or
 
ATG start sites, three codons apart.
 
A start codon polymorphism (SCP) has been 
noted
 
in the first ATG. Thus, the VDR gene from individuals with the T variant 
(containing the restriction site of FokI restriction enzyme, and thus denoted f 
allele), possesses 2 potential translation initiation codons. Therefore, while the 
translation of the VDR mRNA from the T (f) allele can initiate from the first start 
site, translation of mRNA from the C (F) allele  must initiate from the second start 
site as shown in the following illustration: 
 
Normal: (T or f allele)  
(translated to MI (427aa) VDR) 
 
                    ATG                         3 codons apart                         ATG    
               (1st Start codon)                                               (2nd  potential start codon) 
                   ↓ 
Polymorphic varient: ( C or F allele)  
(translated to M4 (424aa) VDR) 
 
                                 ACG                                                      ATG 
                                                                                   (only one start codon) 
                                                             
  
Such a difference, may provide structural change in the VDR protein that could 
potentially alter its function and thereby influence bone remodeling
 
and bone 
mineral density (BMD). Interestingly, this T-C transition results in a three amino 
 26 
acid shorter protein (424 aa residue(M4 isoform )instead of 427(M1 isoform))with 
increased biological activity (Harris etal.1997,Arai etal. 1997, Haussler etal,1998, 
Uitterlinden,2004b). In a more recent study on VDR gene polymorphism and 
osteoporosis, it was reported that the FokI SCP is strongly associated with reduced 
bone mineral density and predisposes women to Osteoporosis at the lumber spine 
(as seen in the next section).  
 **In Sydney, Morrison et al  carried out a study on MZ and DZ twins, where bone 
density was measured at different anatomical positions and correlated with VDR 
genotypes. From the results obtained, the b allele (containing the BsmI
 
restriction 
site) was associated with higher bone density and greater difference in bone 
densities at the lumbar spine was observed in DZ twins. Morrison et al described 
that allelic variations of the VDR gene accounts for 75% of the genetic effects on 
bone density and that VDR polymorphisms can be used to predict an increased risk 
of osteoporosis(Morrison etal,1994). This was the first study that showed such a 
correlation and since then, various studies have been carried out on different ethnic 
groups and different age groups to try to determine whether a correlation exists 
between these polymorphisms and BMD. However, among the most 
polymorphisms that seem to be associated with BMD in many studies are the BsmI 
and the FokI polymorphisms on which the following section will  concentrate. 
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1.3.5.Overview About Previous Studies On BsmI & FokI Polymorphisms: 
   Of particular interest in this respect is the fact that not always the same risk allele 
is being found associated with bone parameters, preventing the straight forward 
interpretation of these associations: Surprisingly, while the initial studies by 
Morrison et al (1992,1994,1997) suggested the "B"allele of the BsmI-RFLP site to 
be the risk allele associated with low BMD, other studies either confirmed this, 
didn't find any effect, or found the opposite (i.e.the"b"allele to be the risk allele 
associated with low BMD) (Uitterlinden etal.2002). For example, contrasting the 
results obtained by Morrison et al are those of Hustmyer et al,1994, where no 
correlation was found between different VDR genotypes and BMD. This study was 
carried out on MZ and DZ twins of Caucasian origin at the Indiana University 
where ApaI, TaqI and BsmI were used as restriction enzymes. Hustmyer et al  
argued that the different results obtained from Morrison`s work may be due to the 
fact that VDR polymorphisms may be linked to another gene locus involved in 
bone density regulation. They also emphasized that this genetic linkage may be 
obscured by environmental factors that are particular to different populations 
(Hustmyer etal,1994).  
   Moreover, contrasting results were obtained in a study carried out on southern 
Chinese females (Kung etal.1998). The frequency of the B allele in this population 
was found to be lower when compared to that of western countries but is similar to 
that found in Koreans (Lim etal.1995). Kung et al , 1998 tried to find an 
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explanation for the various conflicting results obtained from the various studies. 
The role of environmental factors in the genetic effects of the VDR on BMD, 
especially dietary calcium intake, was highly emphasized. It was also stated that 
since the BsmI cleavage site is found in an intronic region, there is no actual 
difference in VDR expression between BB and bb genotypes. So it was concluded 
that VDR polymorphisms do not predict an increased risk of osteoporosis.  
   In another study carried out in the UK , an inverse association was found 
between VDR genotypes and BMD at the hip (Houston etal.1996). Unlike most of 
the studies, Houston et al  found a lower BMD in individuals having the bb 
genotype when compared to the BB genotype (-0.79 sd). From this study, it was 
concluded that the VDR genotypes are associated with BMD in the population 
studied, explaining that the inverse findings found may reflect that reduced BMD 
may not be a direct cause of the VDR genotype but may be linked to another 
disease causing locus nearby. While Various studies were carried out on the BsmI 
restriction site showing its association with BMD, Lim et al concluded that VDR 
polymorphisms are not helpful in predicting osteoporosis (Lim etal.1995).  
   Considering the FokI polymorphism, A promising association between ff 
genotype and low BMD at the lumbar spine in a cohort of postmenopausal women 
has been published by Gross et al (1996) (Zajickova,2003). Moreover, In a study 
carried out in Boston in 1997, Harris and co-workers showed that postmenopausal 
women with the ff genotype (containing the FokI restriction site) had lower 
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femoral BMD (7.4%) when compared to the FF genotype. They also observed that 
a small difference in the distribution of these SCPs between black and white 
populations might explain part of the racial differences in BMD at the femoral 
neck (Harris etal.1997). Surprisingly, conflicting results were obtained by Ferrari 
et al, when they did not find correlation between VDR SCP and BMD in 
European-Caucasian women (Ferrari etal,1998). Interestingly, Kubota et al 
concluded that the FokI polymorphism is a stronger genetic indicator of 
osteoporosis than the BsmI polymorphism in pre-menopausal Japanese women 
(Kubota etal.2001), while van der Sluis et al predicted that VDR polymorphism 
predict height and bone size rather than bone density in children and young adults 
(van der Sluis etal.2003).                                                                                                                 
***Table 1.3,and table 1.4 below summarise various association studies 
(concerning the BsmI & FokI polymorphisms) with positive and negative findings 
respectively. Such conflicting findings – which aren't exclusive for the field of 
genetic association analysis – could have several reasons: The most likely 
explanations are that given the small effect on BMD, very often the statistical 
power is much too low and no conclusions on the presence or absence of an effect 
can in fact be drawn. Moreover, interaction between different genes and /or 
environmenta1 factors play a role in the action of this important steroid hormone 
receptor transcription factor. For example, dietary Ca-intake is known to differ 
substantially between countries while circulating serum vitamin D levels, which 
are determined by several metabolizing enzymes, also differ between populations. 
 30 
Consequently, such gene-gene and gene-environment interactions can of course 
differ between different populations (Uitterlinden etal.2002).This is shown in table 
1.5, where a summary of studies on this topic are shown.  
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Table 1.3 : Association studies with positive findings in the VDR gene (Bsm-I & Fok-I RFLPs). 
 
Reference P -value Phenotype and effect Population 
characteristics 
n Marker 
locus 
Morrison 
et al. 1994 
LS (0.000054, FN 
(0.038) 
BMD of LS, FN  Normal healthy 
white twins 
250 BsmI 
Morrison 
et al. 1992 
BB vs bb: 0.0001 Osteocalcin concentration 
(BB>bb) 
White individuals 91 BsmI 
Tokita et 
al. 1996 
 BMD (Bb<bb) 
Bone turnover: levels of 
osteocalcin, alkaline phosphate. 
1,25-dihydroxyvitamin D 
(Bb>bb) 
FN BMD (bAT<other haplotypes) 
Normal healthy 
premenopausal 
Japanese women 
202 BsmI 
Salamone 
et al. 1996 
 Spinal and trochanter BMD 
(BB>Bb, bb) 
Healthy 
premenopausal 
women, aged 44-50 
yr 
470 BsmI 
Houston et 
al. 1996 
<0.02 FN bone density (bb<BB) Pre-and 
postmenopausal 
women 
171 BsmI 
Sainz et al. 
1997 
0.04 (for bb>BB) 
0.03 (for bb>BB) 
Femoral BMD (bb>BB) 
Lumbar vertebral BMD (bb>BB) 
Normal prepubertal 
American girls of 
Mexican descent 
100 BsmI 
Harris et 
al. 1997 
0.015 
0.042 (total body 
BMD) 
0.001 (FN) 
Whole-group FN BMD (ff<FF) 
White: total body BMD, FN 
BMD (ff<FF) 
Premenopausal 
American women 
(72 black and 82 
white) 20-40 yr 
154 FokI 
Gross et al. 
1996 
0.01 
0.005 
 
LS BMD (ff<Ff<FF) 
Decrease in BMD at FN in 2 yr 
(ff>FF) 
Postmenopausal 
Mexican-American 
white women 
100 FokI 
Arai et al. 
1997 
<0.05 LS BMD (mm>MM) Premenopausal 
Japanese women 
110 FokI 
Krall et al. 
1995 
0.01 FN BMD (BB lowest among 
women >10 yr menopausal), rate 
of bone loss over 2 yr at spine, 
FN, radius (BB>other) 
Healthy 
postmenopausal 
women 
229 BsmI 
Ferrari et 
al. 1995 
<0.05 for BB, 
<0.03 for Bb 
 
<0.03 (for Bb) 
LS BMD loss over 18 months 
(BB, loss; bb, no loss; Bb, change 
correlated with calcium intake) 
Change in LS BMD in reaction to 
calcium intake (Bb) 
Elderly individuals 72 BsmI 
Dawson-
Hughes et 
al. 1995 
0.044 Fractional calcium absorption at 
low calcium intake (BB<bb) 
Healthy late 
postmenopausal 
women 
60 BsmI  
Kiel et al. 
1997 
 
 
<0.05 
Effect of calcium intake on BMD 
increase only in bb subjects 
FN BMD (bb>BB) 
White aged 69-90 yr 
 
White aged 18-68 yr 
328 
 
94 
BsmI 
Ongphiph-
adhanakul 
et al. 1997 
0.05 24 h urinary calcium excretion 
(bb>BB) 
Thai 
postmenopausal 
women 
84 BsmI 
Ames et al. 
1999 
0.02 
0.04 
BMD (FF>Ff>ff) 
Calcium absorption (FF>Ff>ff) 
Healthy children 
aged 7-12 yr 
72 FokI 
Barger-
Lux et al. 
1995 
 BMC (bone mineral content), 
weight (bb>Bb>BB) 
Healthy 
postmenopausal 
women 
32 BsmI 
Vandevyv-
er et al. 
1997 
0.04 FN BMD (bb>BB) Non-obese 
postmenopausal 
women (BMI<30 
kg/m ) 
558 BsmI 
Viitanen et 
al. 1996 
LS, 0.030 
FN, 0.049 
Peak bone mass 
BMD in LS, FN (bb>BB) 
Yoyng Finns, 20-29 
yr 
75 BsmI 
 
Continued 
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Reference P -value Phenotype and effect Population 
characteristics 
n Marker 
locus 
Fleet et al. 
1995 
FN BMD (0.034) 
LS BMD (0.036) 
FN BMD (whole group) 
(bb,Bb>BB) 
(white) 
(black) 
83 
72 
BsmI 
Kiel et al. 
1997 
<0.05 
 
 
<0.05 
<0.05 
Trochanter BMD (bb>Bb, BB) 
 
 
FN BMD (bb>BB) 
FN BMD (bb>BB) 
Old people (60-90 
yr) with calcium 
intake >800 mg/day 
18-68 yr 
Men from the above 
population 
118 
 
 
94 
50 
BsmI 
Geusens et 
al. 1997 
<0.05 
<0.01 
<0.05 
FN BMD (bb>BB) 
Quadriceps strength (bb>BB) 
Grip strength (bb>BB) 
Healthy women 
older than 70 yr, 
non-obese (BMI<30 
kg/m ) 
380 BsmI 
Lazaretti-
Castro et 
al. 1997 
<0.05 LS BMD (bb>BB), FN BMD 
(bb>Bb>BB) 
Brazilian women, 
20-47 yr, 
premenopausal 
127 BsmI 
Tamai et 
al. 1997 
<0.035 LS BMD (bb>Bb) Japanese women, 
healthy, 43   17 yr 
92 BsmI 
Tamai et 
al. 1997 
<0.025 LS BMD (BB>bb) Japanese women, 
osteoporosis, 71   10 
yr 
90 BsmI 
Hauache et 
al. 1998 
 LS, FN BMD (BB<Bb,bb) Brazilian patients 
with IDDM 
78 BsmI 
Graafmans 
et al. 1997 
0.03 Increase of BMD in response to 
vitamin D supplementation (BB, 
Bb>bb) 
Old women, >70 yr 81 BsmI 
Howard et 
al. 1995 
0.01 Increase in serum osteocalcin 
after 7-day oral 1,25(OH)  
stimulation (BB<bb) 
Premenopausal 21 BsmI 
Suarez et 
al. 1997 
 Body length, weight, surface area 
(BB girls>bb girls, BB boys<bb 
boys) 
Healthy infants 589 BsmI 
Need et al. 
1996 
0.030 (bone 
density) 
0.026 (bone area) 
Bone density in the forearm 
(BB<Bb,bb) 
Bone area in the forearm 
(BB>Bb,bb) 
Normal men aged 
20-83 yr 
146 BsmI 
Heaney et 
al. 1997 
 Femoral shaft expansion, increase 
in cortical area (bb>other) 
Middle-aged white 
women 
170 BsmI 
Kobayashi 
et al. 1998 
 BMD in radius (bb<BB, Bb) Japanese patients 
with primary 
hyperparathyroid-
ism 
66 BsmI 
Karkoszka 
et al. 1998 
<0.02 Decrease of whole-body and FN 
BMD during 18 months (BB>Bb, 
bb) 
Japanese 
hemodialysed 
patients 
88 BsmI 
Gennari et 
al. 1997 
0.0015 Intestinal Ca  absorption (Bb<bb) White 
postmenopausal 
women aged 61   
0.6 yr 
120 BsmI 
Lucotte et 
al. 1999 
Significant FN BMD (ff<FF, Ff) Postmenopausal 
osteoporotic French 
women aged 45-75 
yr 
98 FokI 
Kikuchi et 
al. 1999 
0.001 BMD loss in both early and late 
postmenopausal women (Bb>bb) 
Postmenopausal 
Japanese women 
191 BsmI 
Ferrari et 
al. 1998a 
<0.02 LS BMD, height (BB<Bb, bb) Prepubertal girls 
and peri- and 
postpubertal 
adolescents of white 
origen 
197 BsmI 
Continued 
 
 
 
 33 
Reference P value Phenotype and effect Population 
characteristics 
n Marker 
locus 
Lorentzon 
et al. 2000 
0.01 (height at 
birth) 
0.01 (growth after 
birth) 
0.005-0.008 
(height during and 
after puberty) 
<0.05 (bone area) 
Height at birth (BB<Bb, bb), 
growth from birth to age 16.9   
0.3 (BB<Bb, bb), height during 
(age 16.9   0.3) and after puberty 
(age 19.3   0.7) (BB<Bb, bb), 
bone area of humerus, femur and 
total body (BB<Bb,bb) 
Healthy white males 90 BsmI 
Rubin et 
al. 1999 
0.006  Peak BMD at femoral neck (B: 
0<1<2) 
Healthy white 
women aged 18-35 
yr 
677 BsmI 
Ferrari et 
al.1999 
0.03 (LS), 0.05 
(femoral 
trochanter) 
BMD Z scores at LS and femoral 
trochanter (BB<Bb<bb) 
Healthy young men, 
aged 24.3   3.1 yr 
104 BsmI 
Lorentzon 
et al. 2001 
0.02 LS BMD (Bb>bb) Healthy white girls, 
aged 16.9   1.2 yr 
99 BsmI 
Sheehan et 
al. 2001 
 Serum osteocalcin (ff>Ff>FF), 
urinary pyridinoline and 
deoxypyridinoline (ff>Ff>FF 
Healthy Irish adults 
aged 16-67 yr 
118 FokI 
Marc et al. 
2000 
 LS BMD (bb>BB) Late 
postmenopausal 
women aged 47-77 
yr 
102 BsmI 
Langdahl 
et al. 
2000a 
<0.001 (BsmI, 
intertrochanter), 
<0.01 (BsmI, total 
hip) 
BMD of intertrochantic region 
(bb>other) and total hip 
(bb>other) 
192 osteoporotic 
patients, 207 normal 
controls 
399 BsmI 
Gennari et 
al. 1999 
0.06 Lumbar BMD Postmenopausal 
women of Italian 
descent, 164 
osteoporotic, 117 
osteopenia, 119 
normal 
400 FokI 
Gomez et 
al.1999 
 Lumbar and FN BMD of women 
(bb>Bb, BB) 
Individuals of both 
sexes 
326 BsmI 
Marc et al. 
1999 
 Response to cyclic etidronate 
therapy with calcium 
supplementation: LS BMD 
increase (BB, Bb>bb) osteocalcin 
decrease (bb>BB) 
Late 
postmenopausal 
women 
24 BsmI 
Chen et al. 
2002 
0.29 LS BMD (Ff>ff) Postmenopausal 
Chinese women in 
Taiwan 
163 FokI 
Chen et al. 
2001a 
<0.001 Lumbar and FN BMD Postmenopausal 
Chinese women in 
Taiwan 
171 BsmI 
Kim et al. 
2002a 
 LS BMD annual percentage 
change (bb, TT<Bb, Tt) 
Postmenopausal 
Korean women who 
received HRT for 1 
yr 
303 BsmI, 
TaqI 
Deng et al. 
1999 
0.004 ~5.8% spine BMD variation US mid-western 
postmenopausal 
white women 
108 BsmI 
Douroudis 
et al. 2003 
 BMD Hellenic 
postmenopausal 
women 
126 BsmI 
Kim et al. 
2003 
 BMD Postmenopausal 
Korean women 
 BsmI 
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Table 1.4: Association studies with negative findings: 
 
Reference Phenotype Population characteristics n Marker 
locus 
Hustmyer et al. 
1994 
BMD White 86MZ
/39DZ 
BsmI 
Garnero et al. 
1995 
BMD, bone turnover Premenopausal women, white 189 BsmI 
Garnero et al. 
1996 
Arden et al. 
1996 
Bone turnover, rate of bone loss, 
BMD 
Quantitative ultrasound of calcaneus 
or hip axis length 
Postmenopausal women, 1-26 
yr postmenopausal 
Female dizygous twins 
268 
 
189 
BsmI 
Zmuda et al. 
1997 
BMD, rate of postmenopausal bone 
loss, bone turnover 
African-American women >65 
yr 
101 BsmI 
Vandevyver et 
al. 1997 
BMD Type I osteoporotic women 
(66.6   8.4 yr) 
84 BsmI 
McClure et al. 
1997 
BMD, bone metabolism White women of Mexican 
descent, postmenopausal 
103 BsmI 
Eccleshall et 
al. 1998 
BMD, calcium, parathyroid hormone, 
vitamin D, osteocalcin, alkaline 
phosphatase 
Premenopausal French women 174 FokI 
Boschitsch et 
al. 1996 
BMD Postmenopausal women 163 BsmI 
Ongphiphadh-
anakul et al. 
1997 
BMD, osteocalcin Thai, postmenopausal women 84 BsmI 
Graafmans et 
al. 1997 
FN BMD Old women, >70 yr 81 BsmI 
Rauch et al. 
1997 
Markers of bone turnover 
BMD 
Ultrasound transmission velocity 
through bone 
14 premenopausal 
36 postmenopausal 
43.3-62.8 yr 
German women 
50 BsmI 
Tsai et al. 1996 
 
 
Alahari et al. 
1997 
BMD, BMC, markers of bone 
turnover 
 
BMD 
Chinese, 155 men aged 22-88, 
113 premenopausal women 
aged 40-53 yr 
Premenopausal white women 
268 
 
 
69 
BsmI 
Spotila et al. 
1996 
BMD Men from southern Europe 
Premenopausal women from 
eastern Europe 
Postmenopausal women from 
western Europe 
48 
56 
 
80 
BsmI 
Gunnes et al. 
1997 
Forearm BMD gain Young boys and girls, aged 8.2-
16.5 yr 
273 BsmI 
Kinyamu et al. 
1997 
Intestinal VDR protein concentration, 
serum 1,25(OH) D and radioactive 
calcium absorption 
49 young women aged 25-35 yr 
43 elderly women aged 65-83 
yr 
92 BsmI 
Mocharla et al. 
1997 
Abundance of VDR mRNA in 
peripheral blood mononuclear cells 
 38 BsmI 
Gross et al. 
1998a 
Levels of VDR expression, cellular 
responsiveness to 1,25(OH) D  in 
cultured skin fibroblasts 
 9 BsmI 
Jorgensen et 
al. 1996 
BMD at LS, hip, and forearm 
Early postmenopausal bone loss (age 
51-53 yr) 
Late postmenopausal bone loss (age 
63-69 yr) 
Long-term postmenopausal bone loss 
(age 51-69 yr) 
Danish women 723 
110 
 
108 
 
109 
BsmI 
Correa et al. 
1999 
Serum calcium, serum PTH, BMD, 
parathyroid tumor weight, VDR and 
PTH mRNA levels, Ca -PTH set 
points 
Postmenopausal women with 
sporadic primary HPT 
182 FokI 
 
Continued 
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Reference Phenotype Population characteristics n Marker 
locus 
Lucotte et al. 
1999 
Age, yr since menopause, hight, 
weight, BMD at LS and FN 
Postmenopausal osteoporotic 
French women aged 45-90 yr 
124 FokI 
Zmuda et al. 
1999a 
Hip and calcaneal BMD, calcaneal 
ultrasound attenuation, hip geometry, 
biochemical markers of bone 
turnover, fractional calcium 
absorption 
Community-dwelling African-
American women aged >65 yr 
104 FokI 
Kikuchi et al. 
1999 
Gregg et al. 
1999 
LS baseline BMD 
 
BBA, SOS 
Postmenopausal Japanese 
women 
Women aged 45-53 yr 
191 
 
393 
BsmI 
Ferrari et al. 
1998b 
BMD 177 healthy premenopausal 
women aged 18.7-56.0 yr, 155 
prepubertal girls aged 6.6-11.4 
yr 
332 FokI 
Ferrari et 
al.1998a 
BMD Premenopausal women of white 
origin 
172 BsmI 
Willing et al. 
1998 
Baseline BMD, change in BMD over 
3 yr, bone-related serum markers 
Pre- and perimenopausal 
women 
372 BsmI 
Lau et al. 1999 BMD 272 Chinese women (mean age 
75), 237 Chinese men (mean 
age 73 yr) 
509 BsmI 
Hansen et al. 
1998 
Lumbar and femoral baseline BMD, 
bone loss rate, biochemical markers 
of bone metabolism (bone specific 
alkaline phosphatase, urinary 
hydroxyproline, serum osteocalcin) 
Healthy perimenopausal Danish 
white women 
200 BsmI 
Zajickova et 
al. 2002 
BMD Postmenopausal Czech women 
aged 62.5   8.9 yr 
114 
 
BsmI  
 
 
 
 
 
 
 
 
 
 36 
Table 1.5: Gene x gene and gene x non-genetic factor interaction (related to the VDR gene) 
 
 
Referen
ce 
P 
value 
Effect Population Traits Factors 
Ferrari et 
al. 1998b 
 ff was associated with a significant lower LS 
BMD in bb and aa individuals 
Prepubertal whites LS 
BMD 
VDR (FokI) x 
VDR (BsmI 
and ApaI) 
Ferrari et 
al. 1999 
 Among BB, BMD were significantly lower in 
individuals carrying f allele 
104 healthy men, 
aged 20.7-38.6 yr 
BMD VDR BsmI x 
FokI 
Ferrari et 
al. 1998a 
 BMD associated with VDR gene 
polymorphism only before puberty 
(BB<other); BMD accrual was increased in 
Bb and possibly BB prepubertal girls after 
increasing dietary calcium intake, bb 
individuals had the greatest spontaneous 
BMD accrual and remained unaffected by 
calcium supplements 
369 healthy white 
females, aged 7-56 
yr 
BMD VDR x age, 
dietary 
calcium intake 
Graafma
ns et al. 
1997 
0.03 BMD increase in the VitD supplementation 
group was greater in the BB and Bb genotype, 
compared with bb genotype 
81 women, aged 70 
yr and over 
BMD 
increase 
VDR x VitD 
supplementat-
ion 
Kiel et 
al. 1997 
 In bb, not Bb or BB individuals, BMD was 
associated with calcium intake; BMD greater 
in persons with bb genotype only in the group 
with calcium intakes greater than 800 mg/day 
328 individuals 
aged 69-90 yr, 94 
individuals aged 
18-68 yr 
BMD VDR BsmI x 
calcium intake 
Riggs et 
al. 1995 
 Age modulates the effect of VDR genotypes 
on FN BMD such that the effect of genotype 
was greatest among younger (premenopausal) 
women and declined with age so that there 
was no discernible difference by age 70 yr 
139 normal healthy 
women (53.2   14.5 
yr) and 43 severely 
osteoporotic 
postmenopausal 
women (65.8   5.9 
yr) 
FN 
BMD 
VDR x age 
Vandevy
v-er et 
al. 1997 
 Difference in FN BMD by BsmI genotype 
exists only in non-obese women (BMI <30 
kg/m ) 
807elderly women 
(>70 yr) ; 84 
women with 
osteoporosis 
BMD VDR x weight 
Gennari 
et al. 
1999 
0.04 Association of FokI genotypes with lumbar 
BMD more significant amont women in the 
first 5 yr of menopause 
400 
postmenopausal 
women of Italian 
origin 
BMD VDR x years 
since 
menopause 
Rapuri et 
al. 2001 
0.05 When caffeine intake >300 mg/day, spine 
bone loss of tt>TT 
489 elderly women 
(aged 65 -77, 96 
controls 
BMD VDR x 
caffeine 
Denniso
n et al. 
2001 
0.02 Individuals in the lowest third of birthweight, 
spine BMD BB>other 
165 men, 126 
women aged 61-73 
yr 
BMD VDR genotype 
x birthweight 
Drummo
-nd et al. 
2002 
0.03 
 
 
 
 
Older than 60 yr FF>Ff, ff 
Less than 60 yr: no association 
 
 
 
134 
postmenopausal 
Irish women (age 
58.19 - 7.69 yr) 
Bone 
loss 
VDR x age 
 
 
 
 
Tofteng 
et al. 
2002 
 BMI <25 kg/m : f allele associated with lower 
BMD of hip and forearm, b allele associated 
with lower spine BMD. FF, BB women: no 
difference in BMD between obese and thin 
women 
332 healthy early 
postmenopausal 
Danish women 
BMD VDR (FokI, 
BsmI) x BMI 
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1.4.Methylene Tetrahydrofolate Reductase (MTHFR): 
1.4.1.MTHFR Gene and Gene Product: 
    The 5,10-methylenetetrahydrofolate reductase (MTHFR) gene is located on 
chromosome 1 at 1p36.3 (figure 1.13). The complementary DNA sequence is 2.2 
kilobases long and appears to consist of 11 exons. Alternative splicing of the gene 
has been observed . (Goyette etal.1998, Botto&Yang, 2000). 
 Figure 1.13:MTHFR gene locus on chromosome 1   (U.S.National Library of Medicine) 
 
   The major product of the MTHFR gene in humans is a catalytically active 77-
kDa protein (although a smaller isoform of approximately 70kDa has been 
observed in some tissues(Rozen,1997)). MTHFR enzyme (EC 1.5.1.20) catalyzes 
the conversion of 5,10 methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-
MTHF) which is the major circulating form of folate (Figure 1.14).                                                                                                                                       
The biochemical pathways involving folic acid and MTHFR are complex . Briefly, 
5-MTHF(the methylated form of folate) provides the carbon moiety(participating 
in a single carbon transfer)that is used to convert homocysteine into methionine, a 
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reaction catalyzed by methionine synthase(vitamin B12 dependent). The 
remethylation of homocysteine to methionine is an important step in the metabolic 
network that regulates the biosynthesis of nucleosides, the methylation of DNA, 
proteins and lipids, and the levels of homocysteine and methionine . The metabolic 
network is complex and relies on multiple activators and inhibitors. For instance, a 
derivate of methionine, S-adenosyl methionine (SAM), is an allosteric inhibitor of 
MTHFR and an activator of cystathionine ß-synthase and regulates two main 
outflow paths of homocysteine. Although the complete effects of normal and 
abnormal folate metabolism are still incompletely understood, there is growing 
evidence that normal MTHFR activity may contribute to maintaining the pool of 
available circulating folate and methionine and prevent a buildup of homocysteine; 
conversely,abnormally low MTHFR activity may lead to lower levels of 
circulating folate,lower availability of methionine,and higher levels of 
homocysteine, since homocysteine cannot be converted to methionine (Botto & 
Yang,2000).                                                                                                                          
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Figure 1.14:Simplified metabolic pathways involving MTHFR  
 
***MTHFR catalysis the reduction of 5,10-methylene THF to 5-methyl THF(the predominant circulatory form of 
folate, and the methyl group donor required for the remethyation of homocysteine to methionine) (Frosst etal,1995)  
 
1.4.2.MTHFR Gene (C677T)Polymorphism: How is it Related to Osteoporosis? 
   The MTHFR gene has a common polymorphism located to nucleotide 677, and 
is caused by a single base change (or point mutation) that converts a cytosine(C) 
into a thymine (T) leading to an amino acid substitution (alanine to valine) at 
position 222 in the MTHFR enzyme (Cashman,2005). The C677T allele is 
commonly called "thermolabile," because the activity of the encoded enzyme 
(thermobile MTHFR)is reduced at 37ºC or more (Kang,1991). Thus, MTHFR 
activity among C677T homozygotes (denoted TT or VV)is 50-60% lower at 37ºC 
,and approximately 65% lower at 46°C than in similarly treated controls. Hetero-
zygotes (denoted CT or AV)are in the intermediate range. People who are 
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homozygous for the C677T allele tend to have mildly increased blood 
homocysteine levels if their folate intake is insufficient, but normal blood levels if 
their folate intake is adequate (Rozen,1997). 
    In the general population, a mildly elevated plasma homocysteine is a common 
condition. However,high circulating levels of homocysteine (also referred to as 
hyperhomocysteinemia) is  associated with an increased risk of neural tube defects, 
Alzheimer's dementia, pregnancy complications, and inflammatory bowel 
disease.Recently, studies reported that high homocysteine levels significantly 
increase the risk of osteoporotic fracture. Moreover,  association studies linked the 
common allelic polymorphism in the MTHFR gene  with low bone mineral density 
(BMD) and/or fracture risk, together with evidence of generalized osteoporosis in 
patients with homocystinuria, a condition in which there is dramatically elevated 
plasma homocysteine levels. 
   The underlying pathophysiological mechanism for the occurrence of early 
osteoporosis in patients with elevated homocysteine levels is not completely 
understood. However, this finding has been attributed to a competitive inhibition of 
lysyl oxidase, an enzyme that is involved in the synthesis of cross-links that 
stabilize the collagen fibrils in bone, by high homocysteine levels. However, while 
this has been shown clearly in vitro, in vivo evidence of the link between 
homocysteine and generalized osteoporosis is limited (Cashman,2005, 
Morita,1998). 
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1.4.3. Association Studies on MTHFR(C677T) and  Osteoporosis: 
 Recently, a number of studies have investigated the association between the 
MTHFR (C677T) genotype and osteoporosis (although some are contradictory). 
For example, based on the fact that early-onset osteoporosis is associated with 
homocystinurea (Morita etal,1998), and that plasma homocystein concentration is 
higher in postmenoposal than in premenoposal women (Kang&Trelstad, 1973): 
Miyao et al. formulated the hypothesis that homocysteine might participate in the 
pathophysiological process of osteoporosis, and they investigated the influence of 
MTHFR(C677T) polymorphism on BMD. In their study on 307 post-  menopausal 
healthy women, there was a significant effect of the MTHFR (C677T) mutation on 
lumbar spine BMD (with the TT genotype having the lowest BMD) and a trend in 
the same direction for total body BMD. These investigators demonstrated that this 
allelic polymorphism in the MTHFR gene was associated with reduced BMD in 
postmenopausal Japanese women.Actually, this was the first report suggesting that 
the TT genotype is one of the genetic risk factors for low BMD (Miyao etal, 2000). 
Furthermore, Abrahamsen et al. reported that early postmenopausal Danish women 
with the TT MTHFR genotype had significantly lower BMD at the femoral neck, 
hip and spine and increased fracture incidence (Abrahamsen,2003). This was 
further confirmed in two other Danish cohorts (Bathum etal.2004,Villadsen 
etal.2004). In contrast, Jorgensen et al. reported an association between the C677T 
polymorphism (TT) in the MTHFR gene with a reduced risk of osteoporotic 
fracture of the forearm and hip in a case-control study in Danish postmenopausal 
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women relative to those with the wild-type CC genotype, even though BMD at the 
forearm and ultrasound parameters measured at the calcaneus were similar in both 
genotype groups (Jorgensen etal.2002).                                                                          
*The reason for the discordant findings of studies investigating the relationship 
between MTHFR genotype and BMD/fracture risk is unclear (Cashman,2005). 
Dietary factors could be an explanation for this cotraversy, in particular B 
vitamins, which play a role in lowering circulating homocysteine (Bronstrup 
etal.1999 , McKay etal.2000). Results from the Framingham study suggested that 
the discrepancies could also be due to differences in folate status, as the MTHFR 
TT genotype may require -or perhaps induce- low plasma folate for development of 
low BMD (McLean et al.2004). Recently, a key role for riboflavin in preventing 
low BMD in the TT genotype was suggested by analysis of food records in the 
Aberdeen Osteoporosis Screening Study (Macdonald et al.2004) . Analyzing food 
records collected at inclusion to the Danish Osteoporosis Prevention Study, 
Abrahamsen et al.  confirmed reports that BMD in the MTHFR TT genotype is 
only significantly reduced in the lowest quartile of riboflavin, B 12, B6, and folate 
intake, at least at the time of menopause. Vitamin B supplementation would only 
be expected to benefit BMD in about 2% of the population, i.e., those with the TT 
genotype and low vitamin B intake (Abrahamsen etal.2005). 
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 1.5. Aim & Significance of this Study: 
    Osteoporosis represents one of the leading health challenges in most societies 
around the world. The impact of this disease on individual populations depends in 
part on the role of each one of the spectrum of risk factors, the rate of its 
occurrence in the population, and from the relatively high cost of health care of 
inflicted patients. Definitely, prevention programs against osteoporosis are very 
important  in the fight against the development and spread of this disease in the 
population. This strategy is even of higher significance especially in under 
developed  societies and weak economies like our own society.   
    This study is the first of its kind in Palestine. At present, there is no data or 
knowledge concerning the contribution of the various genetic risk factors to the 
occurrence of osteoporosis in our community.  
    In this study, various polymorphic genetic markers that are associated with the 
occurrence of osteoporosis (Bsm-I &Fok-I RFLP of the VDR gene , and the 
C677T polymorphism of the MTHFR gene ) were investigated among women and 
their normal counterparts in Bethlehem district. 
 
 Specific aims of this study: 
1. To investigate the genetic distribution of MTHFR and VDR (Bsm-I & Fok-I) 
polymorphisms among osteoporotic, osteopenic, and normal women (aged 49 
years or more) in our population. 
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2. To study the association between these polymorphisms and BMD at the spinal, 
hip, or femoral neck skeletal sites. 
3. To observe the association of gene – gene interactions with BMD at each of the 
mentioned skeletal sites. 
4. To study the association of other non-genetic environmental factors  including 
years since menopause, weight, and height  with BMD in the different indicated 
genes polymorphisms.  
 
 *Significance of the study : 
1. This will be the first study of its kind among osteoporotic patients in Palestine                                                   
and the  whole Arab population. At the same time, it’s the first study worldwide in 
cross-genotyping the MTHFR gene polymorphisms with the VDR gene 
polymorphisms, and their association with BMD. 
2. It will provide us with better understanding of the genetic markers background 
that is characteristic of our patients in comparison to similar patients from other 
ethnic groups. 
3. Due to the fact that genetic markers are part of the individual’s identity through 
life, the results may provide a very important and powerful tool to test individuals 
at an early age. This will help to identify individuals with  high risk of osteoporosis 
based on their genetic background, and alert them to modify their life style to 
minimize the risk of acquiring the disease or decrease its severity. 
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4. The results can potentially be used in genetic counseling to advise against 
marriages between individuals who are heterozygous for the indicated markers 
especially among families with established history of Osteoporosis. 
5. The results of this study will enhance other similar studies to be done on the 
whole west bank districts other than Bethlehem. 
----------------------------------------------------------------------------------------------------  
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Chapter 2 
                                   Materials & Methods 
 
 
2.1. Sample Collection: 
   In a previous study done by our group, showing the awareness and prevalence of 
osteoporosis among postmenopausal women in Bethlehem district , about 500 women 
were selected according to a personal interview , and then recalled to visit the 
Palestinian Osteoporosis Prevention Society in Beit Jala to perform BMD testing using 
Dual Energy X-ray Absorptiometry ( DEXA ).The target population constituted of 
mixed urban , rural , and camp sub-populations, including  women over 49 years of age, 
from which representative subjects residing in cities, villages, and camp locations were 
selected using a multistage random sampling technique (Intissar Issa, 2004). 
   In this present study, all women from this group who performed BMD testing , 
including osteoporotic , osteopenic , and normal women , were phoned and asked 
if they agree to participate in this study ( by allowing us to collect 5ml  blood 
sample from each , for DNA extraction ). 
   Actually, from  502 women, 344 ( 165 osteoporotic ,  93 osteopenic , and  86 normal 
cases ) agreed to participate . Everyone of these women has known bone scanning 
results, BMDs, disease severity, family history, and other information including age 
since menopause, height, and weight. 
 
 47 
* Table 2.1 describes the sample distribution between the cities, villages, and camp 
locations in Bethlehem district: 
 
Table 2.1: Sample distribution 
 
 
Total Normal 
cases 
Osteopenia 
cases 
Osteoporotic 
Patients 
Location 
 
61 14 18 29 Bethlehem 
56 11 21 24 Beit-Jala 
34 5 10 19 Al-Duhaisha 
Camp 
60 11 17 32 Al-Obeidia 
39 13 10 16 Battier 
35 7 9 19 Al-Khader 
60 25 8 27 Beit-Fajjar 
345 86 93 166 Total 
179 
 
*Blood samples from Bethlehem, Beit Jala, Al-Duhaisha Camp, Al- 
Obeidia, Batteer, and Al-Khader were collected in collaboration with  
Aknaf Beit-AlMaqdes Charitable Society Medical center at Al-Obeidia, 
while the Beit Fajjar blood samples were collected in Al-Haitham  
Medical lab in Beit-Fajjar. 
 
 
 
2.2.  DNA preparation: 
 
 
2.2.1. DNA Extraction: 
     
    EDTA blood samples were collected ( 5 ml when possible ), and centrifuged for 
10 minutes at 3000 rpm . Hemolysed samples were asked to repeated. 
Then , DNA was extracted from the buffy coat using a  commertially available 
kit(Master Pure™ Genomic DNA Purification Kit, Epicentre Technology Co. 
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Cat.No.MG71100). According to this kit, the procedure of DNA extraction  
included the following steps:  
 
 
 
600 µl of the buffy coat was transferred into two  eppendorf tubes, 
(putting 300 µl in each ) 
 
 
 
 Each tube was vortex mixed. 
 
 
 
 
 1200 µl of lysis buffer 1 was added to each tube.  
(this lysis buffer actually makes lysis to the RBCs) 
 
 
 
 The tubes were inverted several times, and their bottom was flicked                                    
(in order to suspend any remaining material) 
 
 
 
After 10 minutes incubation at room temperature, the tubes were 
centrifuged for 25 seconds at highest speed (14000 rpm) in order to pellet 
the WBCs 
 
 
 
Most of the supernatant was pulled off, then the WBCs were 
resuspended in 600 µl of lysis buffer 2 by pipetting the cells up and 
down at least 10 times in order to enhance the lysis of the WBCs 
 
 
 
 250 µl of the precipitation solution was added 
(to precipitate the debris other than the DNA) 
 
 
 
 After vigorous vortex mixing for at least 30 seconds, the debris were 
pelletted by centrifugation for 10 minutes at 14000xg 
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The supernatant was poured into new clean eppendorf tubes 
and 700µl of cold isopropanol was added 
 
 
 
 After inverting the tubes gently for 30-40 times, 
 a stringy precipitate of DNA was visible 
 
 
 
 
The DNA was pelletted by centrifugation for 10 minutes at 14000 rpm, 
and the supernatant was carefully poured off without dislodging the pellet 
 
 
 
The DNA was rinsed twice with cold ethanol in order to wash the isopropanol out 
( by adding 200µl of 75% cold ethanol,centrifuging for 1min,and pouring off 
the ethanol being careful not to dislodge the pellet) 
 
 
 
All of the residual ethanol was then removed with a pipette, 
and the pellet was allowed to air dry at room temperature for 2-3 minutes 
 
 
 
 
Finally, the DNA was dissolved in TE buffer (10mM Tris-HCl and 
1mM EDTA, pH 8.0), and frosen at -30C. 
 
 
 
* Note: this 2-tube procedure for each sample was done for sample 1 until sample 
number 283( In which finally, the contents of each two tubes were mixed 
togetherin one tube). However, samples numbered 284 to 352 were done in a 1-
tube  procedure.  
 
 
 
2.2.2. DNA Quantification: 
     
    DNA samples were quantified spectrophotometrically (Gene Quant II-
Pharmacia Biotech.) at Al-Makassed hospital, after diluting the extracted DNA  
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1:50 by adding 10 µl of DNA to 490 µl TE buffer (10mM Tris-HCL & 
1MmNa2EDTA,pH8) in which the following parameters were assessed: 
-Absorbance at wavelength 230nm: indicating salt concentration. 
-Absorbance at wavelength 260nm: indicating DNA concentration. 
-Absorbance at wavelength 280nm: indicating protein concentration. 
-The ratio 260/280: to show the amount of DNA to proteins (and thus the purity)in 
each extracted sample. 
-DNA concentration in µg/µl for each sample. 
-Protein concentration in mg/ml for each sample. 
 
 
2.3. MTHFR gene (C677T) Polymorphism Screening: 
    The C677T polymorphism of MTHFR of all samples was analyzed using the 
Amplification Refractory Mutation System (ARMS)-PCR.                             
ARMS is a PCR-based method, which uses allele-specific priming. Forward 
primers are designed so that the 3' end  hybridizes to a known polymorphism 
(usually single nucleotide polymorphism (SNP), which can be named as a normal 
sequence or a mutated one), and reverse primers are designed normally. Therefore, 
allele determination requires two PCR reactions (one for each allele) for the same 
genomic DNA, combining both the amplification and diagnostic steps accurately, 
simply, and rapidly. 
 As illustrated in figure2.1 , three primers are utilized in ARMS: a common primer 
(C), a normal specific primer (N), and a   mutation specific primer (M). The mutant 
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primer, coupled with a common primer, is used in one PCR reaction. In parallel, 
the corresponding normal primer coupled with a common primer is used in another 
PCR reaction. Exponential amplification of PCR product requires DNA synthesis 
to be initiated from both the forward and reverse primers. And extension of the 
forward primer cannot occur unless the 3' end is correctly hybridized to the target 
sequence. Which means that each primer should be very specific to amplify a 
particular allele. The presence of an amplification product in the first reaction 
indicates the presence of the mutation, while its absence suggests presence of the 
normal DNA sequence at that specific site. In the second reaction, however, the 
presence of an amplified product suggests presence of a normal DNA sequence at 
that specific site, while its absence suggests presence of the mutation (HUGO Lab 
notes, 2004; Najmabadi etal, 2001; Li etal,1998). 
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Figure2.1  : ARMS-PCR 
 
   Allele 1 reaction  
 
M 
 
 
C 
   Allele 2 reaction 
 
N 
 
 
C 
 
 
 
 
 
 
PCR 
 
 
 
 
 
 
Results per sample:      
1. Allele 1 only  ……………..  Homozygous for allele 1 
2. Allele 2 only  ……………..  Homozygous for allele 2 
3. Both Alleles  ……………..  Heterozygous  
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2.3.1. ARMS-PCR Procedure: 
 
    As detailed in table 2.3, genomic DNA was amplified in a total volume of 25µl 
reaction mixture containing the following: 
 200-500ng of template DNA, (for the first 58 samples, 400ng DNA was used. 
Then, it was found that 200ng DNA was enough, so this amount was used for all 
the remaining samples), with 0.15µg of each primer  (Invitrogen Life 
Technologies, 093018) ( * All the commercially synthesized primers used here, 
and for all the other polymorphisms are listed in table 2.2), 2.5µl of 10X PCR 
buffer (TaKaRa Bio Inc., Code No. R001A. Components: 100mM Tris HCl (pH 
8.3), 500mM KCl, and 15mM MgCl2), 2µl dNTPs (TaKaRa Bio Inc: 2.5mM of 
each dNTP, pH 7-9), and 0.625U of Taq polymerase (TaKaRa Taq TM, Code No. 
R001a) after  completing the total volume up to 25µl with sterile distilled water 
(Birzeit-Palestine Pharm.Co. ). 
 The mixture was then overlaid with one drop of mineral oil (Promega, Catalog # 
DY1151) to prevent vaporization. 
 Finally, the tubes were placed in an automatic thermal cycler ( Gene Amp® PCR 
system 9700  ), so that the PCR amplification was performed according to the 
following conditions: One cycle of initial denaturation at 98º C for 2 minutes, 
followed by 32 cycles of second denaturation at 98º C for 20 seconds, annealing at 
56º C for 30 seconds, and extension at 72º C for 30 seconds, followed by a final 
extension cycle at (72º C) for 10 minutes. 
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* The number of cycles and annealing temperatures and all conditions of all the 
PCRs for all the polymorphism tested, are outlined in table 2.4. 
* Negative control was used by putting TE buffer (10Mm Tris-HCL,pH 8.0 and 1  
 mM  EDTA) , instead of DNA, in the mix. 
* The PCR products (207 bp) of the so called " Normal " primer were denoted "C", 
indicating the C677 polymorphism , while the PCR products (197bp) of the so 
called "Mutant" primer were denoted "T", indicating the T677 polymorphism. 
* In order to be accurate in reading the results, the PCR of every sample giving a 
negative or questionable result in any allele was repeated and read another time.  
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Table 2.2: Primers used in all PCR Protocols: 
 
 
 
Reference Product 
size 
(bp) 
5'-3' Primer 
Sequence 
Primer 
type 
Polymorphism Gene 
George 
Endler 
207 
 
 
 
 
197 
CTCCCTCTCTGA
AGGAGAAGGTGT
CTGCGG 
 
GAAGGAGAAGG
TGTCTGCGGAAG
T 
 
AGGACGGTGCGG
TGAGAGTG 
Normal  
 
 
 
 
Mutated  
 
 
 
Common 
C677T 
polymorphism 
MTHFR 
Tofteng etal, 
2002 
250 AGCTGGCCCTGG
CACTGACTCTG 
 
TCTTCTCCCTCCC
TTTCCACTG 
Sense 
(Forward) 
 
Antisense 
(Reverse) 
Fok-1 
polymorphism 
VDR 
Tofteng etal, 
2002 
820 AACCAAGACTAC
AAGTACCGCGTC
AGTGA 
 
AACCAGCGGGAA
GAGGTCAAGGG 
Forward  
 
 
 
 
Reverse 
Bsm-1 
polymorphism 
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Table 2.3: ARMS-PCR procedure 
 
 
 
 
PCR mix/1 sample Reagents 
Tube 2 (M) Tube 1 (N) 
200-400 ng 200-400 ng Template DNA 1. 
_ 1 µl Normal (N) Primers 0.15 
Mg/Ml 
2. 
1 µl _ Mutated (M) 
1 µl 1 µl Common (C) 
2.5 µl 2.5 µl 10x PCR buffer 3. 
2 µl 2 µl dNTP mixture (2.5 mM each) 4. 
0.125 µl (0.625U) 0.125 µl (0.625U) Taq polymerase (5u/Ml) 5. 
up to 25 µl up to 25 µl Sterile water 6. 
25µl 25 µl Total volume 
 
 
 
 
 
 
 
 
Table 2.4: PCR Conditions for All polymorphisms 
 
 
 
VDR (for Fok-I) VDR (For Bsm-I) MTHFR-C677T PCR 
Conditions 
94 C, 5min 94 C, 2min 98º C, 2min Initial 
denaturation 
 
 
 
 
30 
cycle 
 
95º C, 1min 
 
 
53º C,1min 
 
 
 
72º C,2min 
 
 
 
 
30 
cycles 
 
94º C,30sec 
 
 
60º C,45sec 
 
 
 
72 ºC,1min 
 
 
 
 
32 
cycles 
 
98º C,20sec 
 
 
56º C,30sec 
 
 
 
72º C,30sec 
2
nd
 
denaturation  
 
 
annealing  
 
 
 
extension 
72º C, 5min 72º C, 10min 72º C, 5min Final extension 
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2.3.2. Agarose Gel Electrophoresis: 
 
 
   ARMS products were separated on horizontal 2% (w/v) agarose gels, prepared 
consisting of 2g agarose (GIBCO, Invitrogen Corporation, Cat No. 15510-019) in 
100L 1x Tris Acetate EDTA (TAE) working buffer (10X: 48.4g Tris base 
(Applichem, M=121.14g/mol), 11.42ml glacial acetic acid (CAT No. 5550020, 
m.w.=60.05), 20ml of 0.5M EDTA (pH8) up to 1L D.W.). 
After boiling the mixture, and allowing it to cool (~60ºC), 10µl ethedium 
bromide(10mg/ml) was added to the agarose solution, and mixed thoroughly. 
Then, the warm agarose was poured evenly into a tray containing 2 combs to 
produce wells when the gel was set. After approximately 15 min, the tray was 
placed into an electrophoresis tank (Bio-Rad, sub-cell®GT) filled with 1X TAE 
gel loading buffer. The combs were lifted up carefully, and PCR products were 
loaded into the gel as follows: 
   -3µl of loading dye(Blue/Orange Loading dye,6X,Promega,Cat No.G1881: 
0.03%bromophenol blue,0.03%Xylene cyanol FF,0.4%orange G,15%Ficoll 
400,10mM Tris-HCl (pH8)) was mixed with 10µl PCR product, and loaded into 
each well. 
-For size determination, a ladder marker was  loaded by mixing 1µl of a 100 bp 
DNA ladder(Invitrogen Life Tech., Cat.No.15628 – 019) with 3µl loading dye, and 
9 µl TE buffer, giving bands at 1000, 900, 800, 70, 600, 500, 400, 300, 200,& 100 
bp.  
 58 
-Gels were allowed to run at 120 volt for approximately 20-45 minutes. 
-After electrophoresis, gels were examined and photographed with a Polaroid 
camera (Pharmacia Biotech, Image Master VDS). 
 
 
 
2.4. VDR gene Polymorphisms Screening 
 
- PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) was used for  
 
 the screening of the VDR gene polymorphisms (Bsm-1 and Fok-1-RFLPs). 
 
- This method is based on the principle that treatment of DNA fragments by a 
 
restriction enzyme will show an aberrant pattern if polymorphisms exist in  
 
restriction sites. This aberrant pattern can be detected by ethedium bromide  
 
staining during agarose gel electrophoresis (Tauata etal, 2000). Thus, it is a  
 
useful diagnostic tool to distinguish between homozygous and heterozygous 
 
 alleles, as shown in the schematic representation below: 
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Fig 2.2 : Schematic representation of RFLP-PCR 
 
 
 
 
 
PCR          Amplify a specific gene sequence                          
             containing the wanted RFLP site 
 
 
 
 
 
 
Restriction 
Endonuclease 
Digestion                 Enz + buffer 
 
 
 
 
 
 
 
 
 
 
2.4.1. Bsm-I  RFLP  Screening 
2.4.1.1. PCR Procedure: 
    Amplification of intron 8 of the VDR gene ( containing the Bsm-1 restriction 
enzyme site ) was performed in 30 µl of reaction mixtures, containing: 400 ng of 
gDNA 
Product lacking the 
restriction site of this 
endonuclease 
Product containing the 
restriction site of a certain 
endonuclease 
not cut cut 
Run digestion products on 
agarose gel 
Assign genotypes from the digest 
pattern 
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genomic DNA, with 150 ng of each reverse and forward primers (see table 2.2) , 
3µl of 10X PCR buffer (TaKaRa Bio Inc,Code No.R001A), 2µl dNTPs (TaKaRa 
Bio Inc, containing 2.5mM of each dNTP ), and  0.625U of Taq polymerase 
(TaKaRa Taq™,Code No.R001A) ,after completing the total volume up to 30 µl 
with sterile distilled water (Birzeit-Palestine Pharm. Co.). To prevent vaporization, 
the tubes were overlaid with 1drop mineral oil (Promega, Cat.No.DY1151),and 
finally they were put in an automatic thermal cycler (Gene Amp® PCR system 
9700) according to the conditions described in table 2.4: One cycle of initial 
denaturation at 94ºC for 2 minutes, 32 cycles of second denaturation at 94ºC for 30 
seconds, annealing at 60ºC for 45 seconds, and extension at 72ºC for 1 minute , 
followed by a final extension cycle at 72ºC for 10 minutes. 
*In each run, a negative control was used by putting TE buffer (10Mm Tris-HCL, 
pH 8 and 1mM EDTA) in the mix instead of genomic DNA. 
2.4.1.2. Agarose Gel Electrophoresis for PCR Products: 
   All PCR products (820 bp) were viewed on ~2%(w/v) agarose gels (prepared, 
loaded, and photographed as described in section II.3.2.) in order to determine 
successful amplification. 
2.4.1.3. Bsm-I Enzyme Digestion Procedure: 
      The PCR products were digested with Bsm-I as follows: 
*For the first 152 samples, 10 µl of  PCR products were cleaved by adding a 5µl 
mix containing 1.5 µl of 10X Bsm-I buffer, 5U (0.5µl) Bsm-I enzyme (Roche, Cat. 
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No.1292307, containing 200 units(10U/µl) ), and 3 µl of sterile distilled water 
(Birzeit-Palestine Pharm.Co.). 
*For all samples from 153 up to 345, the volume of the digestion reaction was 
minimized (after testing the new volume on previously tested samples, and 
obtaining the same results), so that 8µl of PCR products were cleaved by adding a 
mix of 1µl 10X Bsm-I enzyme buffer, 0.3 µl of Bsm-I enzyme(Roche, Cat. No. 
1292307), and 2 µl sterile distilled water. 
*The digestion reaction, for all the samples, took place in a water bath (Unitronic-
OR) at 65ºC for 1 hour. 
2.4.1.4. Agarose Gel Electrophoresis for the Digested PCR Products: 
  *  Restriction fragments were visualized by electrophoresis through 1.6%(w/v) 
agarose gels stained with 10µl Ethedium Bromide(10mg/ml), and loaded as 
follows: 
10 µl of the digested products was mixed with 3 µl of Blue/Orange loading dye 
(6X,Promega,Cat.No. G1881),and loaded into each well. 
For size determination , a ladder marker was loaded by mixing 1µl of a 100 bp 
DNA ladder (Invitrogen Life Technologies,Cat. No.15628 - 019) with 3µl loading 
dye and 9 µl TE buffer. 
  * All gels were run at 120 volt , then photographed with a Polaroid camera 
(Pharmacia Biotech., Image Master VDS). 
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  * The uncleaved PCR products of ~820 bp were denoted "B" , and the presence of 
the Bsm-I restriction site (cleaved to 650 bp & 170 bp) was denoted "b", as 
illustrated in figure 2.3. 
 
Figure 2.3 
 
Schematic Diagram Demonstrating the Bsm-I restriction site 
(Restriction Pattern for PCR products) 
 
 
 
 
 
 
                                  Bsm-1 Restriction site 
 
5'                                                                                                              3' 
 
 
 
            After Bsm-1 Enzyme Digestion 
 
 
 
 
 
 820bp            Uncleaved Product                        
     (B-allele)                              
 
 
 
                    170bp      650bp       Cleaved Product                           
  (b-allele)                                
 
   
 
 
   
 
 
 
Exon 7 Exon 8 Exon 9 
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 2.4.2. Fok-I RFLP SCREENING 
2.4.2.1. PCR Procedure: 
      Exon 2 of the VDR gene (containing the restriction site of the Fok-I 
endonuclease) was amplified in 30 µl of reaction mixtures, containing 400 ng of 
genomic DNA, with 150 ng of each reverse and forward primers (see table 2.2), 
3µl of 10X PCR buffer (TaKaRa Bio Inc.,Code No. R001A), 2µl dNTPs (TaKaRa 
Bio Inc. ), 0.625 U of Taq Polymerase (TaKaRa Taq™,Code No.R001A) ,and the 
final volume of 30µl was completed with sterile distilled water (Birzeit-Palestine 
Pharm.Co.) . After overlaying with one drop of mineral oil (Promega, Cat.No. 
DY1151), each tube was placed in the automatic thermal cycler (Gene Amp ® 
PCR system 9700 ) according to the conditions described in table 2.4 : 
One cycle of initial denaturation at 94ºC for 5 minutes , followed by 30 cycles of 
second denaturation at 94ºC for one minute , annealing at 53ºC for 1 minute , and 
extension at 72ºC for 2 minutes , then followed by a final extension cycle at 72ºC 
for 5 minutes. 
* In each run , a negative control was used by putting TE buffer in the mix instead 
of genomic DNA. 
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2.4.2.2. Agarose Gel Electrophoresis for the PCR Products: 
     In order to determine successful amplification, all PCR products (250 bp) were 
viewed on ~ 2% (w/v) agarose gels which were prepared,loaded, and photographed 
as described in section II.3.2. 
 
2.4.2.3. Fok-I Enzyme Digestion Procedure: 
     All PCR products were digested with Fok-I as follows: 
10 µl of PCR products were cleaved with 5U Fok-I (Promega, Cat.No. R6781, 
10u/µl ) , after 3 hours incubation in a water bath (memmert) at 37ºC. 
 
2.4.2.4. Agarose  Gel Electrophoresis for Digested  PCR  Products:   
*  Size separation of the digested PCR products was performed on 3%(w/v) 
agarose gels stained with 10 µl Ethedium Bromide(10 mg/ml), by mixing the 
digested products with 3µl of Blue/orange loading dye ( 6X, Promega, Cat.No. 
G1881) , and loading them in each well. Size determination was achieved by using 
a 100 bp DNA ladder (Invitrogen Life Technologies, Cat.No.15628 – 019) , loaded 
after mixing 1µl of it with 3 µl loading dye and 9 µl TE buffer. 
*  Gels were run at 120 - 150 volt , then photographed with a Polaroid camera 
(Pharmacia Biotech., Image Master VDS). 
* The uncleaved products of 250 bp were denoted "F", while alleles having the 
Fok-I restriction site (and thus cleaved to 56 bp & 194 bp) were denoted  "f".  
(Figure 2.4) 
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Figure 2.4 
 
Schematic Diagram Demonstrating the Fok-I restriction site 
(Restriction Pattern for PCR products) 
 
 
 
 
 
Fok-I restriction site 
 
 
 
  5' 
 
 
                                 After Enzyme digestion               
 
 
 
                                             250bp          Uncleaved Product (F-allele)              
 
 
 
                                   56bp    194bp      Cleaved Product (f-allele)                   
 
 
 
 
 
2.5. Statstical Analysis: 
   Using the standard SPSS package for windows, the frequency distribution of all 
genotypes and other patients' parameters was determined. Chi  square  tests were 
performed  for testing the various polymorphic distributions of MTHFR and VDR 
genes. 
Exon 3 Exon 2 Exon 1 
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   The subjects were classified into three groups according to their genotype. 
Comparison of BMD and other factors among these three groups were performed 
using analysis of variance (ANOVA), followed by Scheffe's post hoc test. When 
the differences in the BMD and other factors were tested between two groups, 
statistical analysis was performed using independent samples' T- test. A  p-value  
less than  0.05 was accepted as the value of significance. 
 
--------------------------------------------------------------------------------------------------- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
Chapter (3) 
Results 
 
 
 
3.1. DNA Quantification : 
   Spectrophotometrically , the following readings were observed: 
In all samples, protein concentration was between 0.1 and 1.3mg/ml, the 260/280 
ratio was between 1.730 and 1.985, and the DNA concentration was approximately 
between 0.1 and 1.3 µg/µl, except for one sample, whose ratio and DNA 
concentration were 1.3 and 0.022 µg/µl respectively. 
 
 3.2. MTHFR ARMS-PCR Results: 
   According to the ARMS-PCR results, MTHFR genotypes in the individual 
samples were denoted: CC,CT,or TT as shown in a representative gel below 
(figure 3.1): 
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bp(C)    207  
 
   
 
     197bp (T) 
 
 12                                1    2    3    4    5    6    7    8    9   10  11 
 
Figure (3.1):Agarose gel electrophoresis for the ARMS PCR of the MTHFR gene: 
- lanes (1-11) upper : represent bands of PCR reactions with the normal primer (C 
allele polymorphism).  
- lanes (1-11) lower :  represent bands of PCR reactions with the mutated primer (T 
allele polymorphism).     
-Lanes 11(upper and lower): are negative controls. 
-Lanes 12(upper & lower): are DNA ladder markers. 
-The genotype results for samples (1-10) are as follows:                                            
          CC,CC,CT,CT,CT,CT,CT,CT,TT,TT. 
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3.3 VDR Gene RFLP Results : 
 
3.3.1 Bsm-I RFLP Results: 
3.3.1.1. Bsm-I PCR Gel Products' Results:  
   The two gels below (figure 3.2  ) show representative Bsm-I PCR products 
(820bp). These amplification bands were then followed by enzyme digestion: 
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A                  820bp 
                                   
                       
 
 
 
 
      1   2   3   4  5   6  7  8  9 10 11 12 13 14 15 16                        
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Figure 3.2:Some of the Bsm-I PCR Products: 
 * Lanes (1-14)A,(1-19)B,and (1-15)C are samples, giving the bands of 820bp size.  
* Lanes 15A & 16C reprersent negative controls. 
* Lanes 16A, 20B, & 17C are DNA ladder markers.   
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3.3.1.2. Results of Bsm-I - Digested PCR Products: 
  According to the gel results, the Bsm-I polymorphisms' genotypes were denoted: 
BB, Bb, or bb.  
Figures (3.3) & (3.4) demonstrate the Bsm-I digestion products results for the 
amplified samples.  
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Homozygous    Heterozygous                                                                                                     
                                                                                                                                     
 
 ◄820 bp            
◄650 bp            
◄170 bp            
 
 
 
 
 
 
◄820bp             
◄650bp             
◄170 bp            
            
 
1    2    3    4   5   6    7   8    9  10 11 12  13  14  15                                       
 
 
Figure 3.3: Results of Bsm-I-Digested  PCR Products: 
-The upper and lower (1-14) lanes :are samples. 
-Lanes 15: are DNA ladders. 
-If the DNA gives only one band (820 bp)-as in the upper lane 1 , this means that   
  the two alleles don't contain the Bsm-1 restriction site, and thus denoted as"BB". 
-If two bands appeared (650bp & 170bp)-as in the upper lanes 2+3, this means that 
  the two alleles contain the Bsm-I  reatriction site, and thus denoted as"bb".        
-If three bands appeared (820bp, 650bp, &170bp) - as in the upper lanes 4+5+6,     
  then this sample is heterozygous, containing one cut allele and one noncut allele,  
  and thus denoted  as"Bb". 
-Accordingly, the genotype results of the samples shown above are: 
  BB, bb, bb, Bb, Bb, Bb, bb, Bb, bb, Bb, Bb, Bb, bb, Bb  in the upper lanes.   
  bb, Bb, bb, Bb, bb, Bb, Bb, bb, Bb, Bb, bb, Bb, bb,bb  in the lower lanes.  
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 820 bp                
650 bp           A 
170 bp                
 
 
 
 
 
 
820 bp               
650 bp          B  
170 bp               
 
 
 
       
 
820 bp                  
650 bp       C        
170 bp                  
 
 
 
 
 
 
820 bp                   
650 bp        D       
170 bp                   
 
 
 
Figure 3.4: Results of Bsm-I digestion of amplified PCR fragments For 76 of the 
Samples: 
* The results were read as followed: 
Row A: Bb,bb,Bb,bb,Bb,Bb,BB,Bb,bb,bb,BB,Bb,Bb,BB,bb,bb,bb,bb,bb 
Row B: bb,Bb,Bb,Bb,bb,bb,bb,bb,bb,bb,Bb,bb,Bb,Bb,Bb,Bb,Bb,Bb,bb 
Row C: Bb,BB,Bb,Bb,bb,Bb,bb,bb,bb,Bb,bb,bb,BB,bb,Bb,bb,bb,Bb,Bb 
Row D: BB,bb,BB,bb,Bb,bb,BB,bb,Bb,bb,bb,BB,BB,BB,Bb,Bb,BB,Bb 
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3.3.2. Fok-I  RFLP Results: 
3.3.2.1. Fok-I  PCR Gel Products' Results: 
  The Fok-I PCR products are 250 bp. The amplified products  were then digested 
by Fok-I enzyme. Two of the PCR gels are shown in figure (3.5). In addition to the 
samples PCR products, each gel contains a negative control and a DNA ladder 
marker . Nonspecific bands appeared,but these bands had no effect on interpreting  
the results: 
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◄250 bp 
 
 
 
◄250 bp 
 
                              
   
250 bp 
 
 
 
 
 
 
250 bp    
 
 
Figure 3.5: Products of Fok-I Digestion of amplified PCR fragments: 
* The last lane of each row is a DNA ladder. 
* The 34 samples of each gel gave a 250 bp band ,ending with a negative control. 
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3.3.2.2. Gel Results for Fok-I - Digested PCR Products: 
   The three genotypes of the Fok-I polymorphisms are denoted: FF, Ff, or ff,        
and demonstrated in figure (3.6) . 
    Figures 3.7 &  3.8 show the results of nine and fourteen of the samples 
respectively.  
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Homozygous                               Heterozygous                            Homozygous 
           
 
 
 
                                          
 
250 bp                                                             
3                                                        250 bp                                                                        194bp                    
                                 
 
   56 bp                                                                
              
                                                                                                         
1       2       3      4                             1        2                                                            1       2      3      
             
A                                               B                                            C 
 
 
 
Figure 3.6: Reading the Fok-I Polymorphisms' Genotypes: 
* The lanes 4A, 2B, and 3C are DNA ladders.  
* The uncleaved products of 250 bp were denoted "FF", as in 1A, 2A, 3A, and 2C. 
* The totally cleaved products_giving the two bands:194 bp & 56 bp were denoted 
  "ff", as  in 1C . 
* The products giving three bands (as 1B) are heterozygous, denoted "Ff". 
* The band appearing between 250 & 194 is a nonspecific band, which didn't affect 
   the reading of the results.  
 
 
 
 
 78 
 
 
 250 bp                
194 bp                 
 
56 bp                   
 
 
                       1        2        3       4       5       6       7       8      9               10                              
 
Figure 3.7: 
Agarose Gel Electrophoresis Result For 9 Samples After Fok-I Digestion: 
The samples' genotypes (1 to 9) were denoted: FF, FF, Ff, Ff, FF, FF, FF, FF, FF. 
 
 
 
 
                                
 
 
 
 
250b        
194bp      
 
56bp       
 
 
 1    2     3     4    5    6     7     8    9  10    11    12  13   14    15 
 
Figure 3.8:Agarose Gel Electrophoresis Result For 14 Fok-I Digested Samples: 
According to the gel, the samples genotypes (from 1 to 14) were read as: 
 FF, Ff, ff, FF, Ff, Ff, Ff, FF, FF, Ff, FF, Ff, FF, Ff.  
 
 
 79 
3.4. Genotype Distribution of MTHFR & VDR Genes' Polymorphisms:   
 
3.4.1. Among The Whole Population: 
   * Figures 3.9, 3.10, and 3.11  show three tables - each followed by a histogram - 
demonstrating the genotypic or allelic frequency of MTHFR, Bsm-I, and Fok-I 
polymorphisms respectively: In all the 345 tested samples, it is noticed that among 
the Bsm-I genotypes, Bb had the highest frequency (Bb=47%) in this population. 
On the other hand, the FF genotype  had the highest frequency among the three 
Fok-I  genotypes (FF= 56.5%). However, the most noticeable result is in MTHFR, 
where the majority of the population were heterozygous (CT= 89.3%) , some had 
the TT homozygous genotype (TT=9.9%), while there was a relative lack of the 
CC genotype (only 0.9%).  
   *Cross-genotyping was done between the MTHFR, the Bsm-I, and the Fok-I 
polymorphisms (figures 3.12, 3.13, and 3.14). However, no significant association 
in distribution was observed between any of these genotypes (p >0.05, Chi square 
tests). 
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Figure 3.9: The frequency of MTHFR genotypes among all the entire, tested 
samples: 
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Figure 3.10: The Frequency of Bsm-1genotypes among the entire tested samples: 
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Figure 3.11: The Frequency of Fok-I genotypes among the entire tested samples 
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Figure 3.12:Cross- Genotyping of MTHFR with Bsm-I & Fok-I Polymorphisms 
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Figure 3.13: Cross-Genotyping of Bsm-I with MTHFR & Fok-I 
 
 
 
Bsm-1 RFLP
bbBbBB
Pe
rc
en
t
80
70
60
50
40
30
20
10
0
MTHFR polymorphysem
CC
CT
TT
 
 
 
 
 
 
Bsm-1 RFLP
bbBbBB
P
e
rc
e
n
t
60
50
40
30
20
10
0
FOKIRFLP
FF
Ff
ff
 
 
  
 
 
 
 
 85 
Figure 3.14: Cross Genotyping of Fok-I with MTHFR & Bsm-I 
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3.4.2. Among the Osteoporotic, Osteopenic, and Normal Cases: 
   The tables below (tables(3.1) to (3.9))describe the various genotypic distribution 
of the VDR and MTHFR genes' polymorphisms among the three cases – classified 
as osteoporosis, osteopenia, or normal  according to their measured BMD in either 
the hip, spine, or femoral neck skeletal sites. 
   The numbers shown in these tables give us a descriptive image. However, 
significant associations with BMD, after statistical analysis to these data, are 
shown in the next sections .  
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Table 3.1: The Distribution of MTHFR Gene Polymorphism Among Hip 
Osteoporotic, Osteopenic, & normal Cases 
 
 
 
 
 
  MTHFR genotype  Hip Fracture Risk  
 Total TT CT CC    
57 5 52 - No. osteoporosis  
 100.0% 8.8% 91.2% 0% % within hip fracture risk   
        
 16.5% 14.7% 16.9%  
% within MTHFR 
genotype 
  
        
163 10 153 - No. osteopenia  
 100.0% 6.1% 93.9% 0% % within hip fracture risk   
        
 47.2% 29.4% 49.7%  
% within MTHFR 
genotype 
  
        
125 19 103          3 No. normal  
 100.0% 15.2% 82.4% 2.4% % within hip fracture risk   
        
 36.2% 55.9% 33.4% 100.0% 
% within MTHFR 
genotype 
  
        
345 34 308        3 No. 
Total 
T
o
t
a
l      
 1 00.0% 9.9% 89.3% 0.9% % within hip fracture risk   
        
I 100.0% 100.0% 100.0% 100.0% 
% within MTHFR 
genotype 
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Table 3.2: Bsm-I Genotypic Distribution Among Hip Osteoporotic, Osteopenic, & 
Normal Cases 
 
 
  Bsm-1   
re 
Hip Fracture 
       RFLP  Risk 
Total bb Bb  BB   
57 14 32  11 No. osteoporosis 
100.0% 24.6% 56.1% 19.3% % within hip fracture risk  
16.5% 11.2% 19.8% 19.0% % within Bsm-1 RFLP  
163 60 73  3C No. osteopenia 
100.0% 36.8% 44.8% 18.4% % within hip fracture risk  
47.2% 48.0% 45.1% 51.7% % within Bsm-1 RFLP  
125 51 57  17 No. normal 
100.0% 40.8% 45.6% 13.6% % within hip fracture risk  
36.2% 40.8% 35.2% 29.3% % within Bsm-1 RFLP  
345 125 162 58 No. 
Total 
 
100.0% 36.2% 47.0% 16.8% %within hip fracture risk  
100.0% 100.0% 100.0% 100.0% % within Bsm-1 RFLP  
 
 
 
 
 
Table 3.3: Fok-I Genotypic Distribution Among  Hip Osteoporotic, Osteopenic,  
& Normal Cases 
 
 
  FOKI RFLP   
 
 
Hip Fracture 
Risk 
Total ff Ff FF    
57 3 20 34 No.  osteoporosis 
100.0% 5.3% 35.1% 59.6% % within hip fracture risk   
16.5% 12.0% 16.0% 17.4% % within FOKI RFLP   
163 12 54 97 No.  osteopenia 
100.0% 7.4% 33.1% 59.5% % within hip fracture risk   
47.2% 48.0% 43.2% 49.7% % within FOKI RFLP   
125 10 51 64 No.  normal 
100.0% 8.0% 40.8% 51.2% % within hip fracture risk   
36.2% 40.0% 40.8% 32.8% % within FOKI RFLP   
345 25 125 195 No.  Total 
100.0% 7.2% 36.2% 56.5% % within hip fracture risk   
100.0% 100.0% 100.0% 100.0% % within FOKI RFLP   
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Table 3.4: The Distribution of MTHFR Gene Polymorphism Among Spinal 
Osteoporotic, Osteopenic, & Normal Cases 
 
 
 
 
 
 MTHFR  Genotypes  
Spinal 
Fracture Risk 
Total TT CT CC   
126 10 116  
No. osteoporosis 
    
100.0% 7.9% 92.1%  % within spinal  
    fracture risk  
36.6% 29.4% 37.8%  % within MTHFR  
    Genotype  
124 6 118  No. osteopenia 
100.0% 4.8% 95.2%  % within spinal  
    Fracture risk  
36.0% 17.6% 38.4%  % within MTHFR  
    Genotype  
94 10 73            No.               3 normal 
 
   
 
% within spinal 
 
    
100.0% 19.1% 77.7% 3.2% Fracture risk  
27.3% 52.9% 23.8% l00.0% % within MTHFR  
    Genotype  
344 34 307 3 No. Total 
100.0% 9.9% 89.2% 0.9% % within spinal  
    Fracture risk  
100.0% 100.0% 100.0% 100.0% % within MTHFR  
    Genotype  
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Table 3.5: Bsm-I Genotypic Distribution Among Spinal Osteoporotic, Osteopenic, 
& Normal Cases 
 
  
Bsm-1 
RFLP 
  
Spinal 
Fracture Risk 
Total bb Bb BB   
126 43 55 28 No. Osteoporosis 
100.0% 34.1% 43.7% 
 %within spinal  
22.2% fracture risk  
36.6% 34.7% 34.0% 48.3% % within Bsm-1 RFLP  
124 46 63 15 No. Osteopenia 
100.0% 37.1% 50.8% 12.1 % 
% within spinal  
fracture risk  
36.0% 37.1 % 38.9% 25.9% % within Bsm-1 RFLP  
94 35 44 15 No. Normal 
100.0 % 
37.2% 46.8% 
16.0% 
% within spinal  
  fracture risk  
27.3% 28.2% 27.2% 25.9% % within Bsm-1 RFLP  
344 124 162 58 No. Total 
100.0% 36.0% 47.1% 16.9% 
% within spinal  
fracture risk  
100.0% 100.0% 100.6% 100.0% % within Bsm-1 RFLP  
 
 
Table 3.6: Fok-I Genotypic Distribution  Among Spinal Osteoporotic, 
Osteopenic, & Normal Cases 
 
  FOKI  RFLP    
Total ff Ft FF  
Spinal Fracture 
Risk 
126 
12 
42 
72 No. osteoporosis 
  
100.0% 9.5% 33.3% 57.1% % within spinal  
    fracture risk  
36.6% 48.0% 33.9% 36.9% 
% within FOKI 
RFLP 
 
124 6 50 68 No. osteopenia 
100.0% 4.8% 40.3.%  % within spinal  
   54.8% fracture risk  
36.0% 24.0% 40.3% 34.9% 
% within FOKI 
RFLP 
 
94 7 32 55 No. normal 
100.0% 7.4% 34.0%  % within spinal  
   58.5% Fracture risk  
27.3% 28.0% 25.8% 28.2% 
% within FOKI 
RFLP 
 
344 25 
124 195 No. 
Total 
   
100.0% 7.3% 36.0%  % within spinal  
   56.7% fracture risk  
100.0% 100.0% 100.0% 100.0% 
% within FOKI 
RFLP 
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Table 3.7 
 The Distribution of MTHFR Gene Polymorphisms Among the Femoral Neck  
Osteoporotic, Osteopenic, & Normal Cases 
 
 
 
 
 
 MTHFR Genotypes  
Femoral 
Neck Risk 
Total TT CT CC   
98 4 94  No. osteoporosis 
100.0% 4.1% 95.9%  
% within neck 
risk 
 
    
% within 
MTHFR 
 
28.4% 11.8% 30.5%  Genotype  
      
163 16 146           No.               1 osteopenia 
100.0% 9.8% 89.6% 0.6% 
% within neck 
risk 
 
    
% within 
MTHFR 
 
47.2% 47.1% 47.4% 33.3% genotype  
      
84 14 68 2 No. normal 
100.0% 16.7% 81.0% 2.4% 
 
% within neck 
risk 
 
    
%within 
MTHFR 
 
24.3% 41.2% 22.1% 66.7% genotype  
      
345 34 308         No.                    3 Total 
100.0% 9.9% 89.3% 0.9% 
%within neck 
risk 
 
    
% within 
MTHFR 
 
100.0% 100.0% 100.0% 100.0% genotype  
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Table 3.8: Bsm-I Genotypic Distribution Among the Femoral Neck Osteoporotic, 
Osteopenic, & Normal Cases 
 
 
 
  
Bsm-1 
RFLP 
  
Femoral Neck 
Risk 
 
Total bb Bb BB    
98 33 47 18 No.  
100.0% 33.7% 48.0% 18.4% % within neck risk Osteoporosis  
28.4% 26.4% 29.0% 31.0% % within Bsm-1 RFLP   
163 59 75 29 No. Osteopenia  
100.0% 36.2% 46.0% 17.8% % within neck risk   
      
47.2% 47.2% 46.3% 50.0% % within Bsm-l RFLP   
84 33 40 11 No. Normal 
 
 
100.0% 39.3% 47.6% 13.1% % within neck risk   
24.3% 26.4% 24.7% 19.0% % within Bsm-l RFLP   
345 125 162              No.                            58 
Total 
  
100.0% 36.2% 47.0% 16.8% % within neck risk   
100.0% 100.0% 100.0% 100.0% % within Bsm-1 RFLP   
 
 
 
 
Table 3.9: Fok-I Genotypic Distribution Among the Femoral Neck Osteoporotic, 
Osteopenic, & Normal Cases 
 
 
 
  
FOK-I  
RFLP 
  
Femoral Neck 
Risk 
Total ff Ft FF   
98 5 32 61 No. osteoporosis 
100.0% 5.1% 32.7% 62.2% % within neck risk  
28.4% 20.0% 25.6% 31.3% % within FOKIRFLP  
163 12 57 94 No. osteopenia 
100.0% 7.4% 35.0% 57.7% % within neck risk  
47.2% 48.0% 45.6% 48.2% % within FOKIRFLP  
84 8 36 40 No. normal 
100.0% 9.5% 42.9% 47.6% % within neck risk  
24.3% 32.0% 28.8% 20.5% % within FOKIRFLP  
345 25 125 195 No. Total 
100.0% 7.2% 36.2% 56.5% % within neck risk  
100.0% 100.0% 100.0% 100.0% % within FOKIRFLP  
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 3.5. Genetic Association  Analysis Results: 
3.5.1. MTHFR & VDR Genotypes' Association with BMD: 
  * Among the MTHFR genotypes, the homozygous TT and CC were associated 
with significantly higher spinal BMD compared to CT (for TT: p=0.03, ANOVA; 
p=0.009, T-test. For CC: p=0.03, ANOVA). In the hip or femoral neck, however, 
no significant BMD differences were observed . Among osteoporotic patients, no 
significant change in BMD was observed in any skeletal site. 
  * The BB genotype of the Bsm-I site was significantly associated with  lower 
BMD at the total hip than the bb genotype ( p=0.026 , ANOVA), while no 
significant differences appeared at the other skeletal sites. Interestingly, among 
spinal osteoporotic women, a significant lower BMD was observed in Bb than in 
bb genotypes (p=0.016, ANOVA) (See table 3.10). 
Table 3.10 : MTHFR & VDR Genotypes' Association with BMD:
>0.05__VDR (Fok-I)
0.026BB<bbhipVDR (* Bsm-I) 
0.03TT,CC>CTspineMTHFR 
(C677T)
P-valueEffectBMD sitePolymorphism 
*Among spinal osteoporotic women, a significant lower BMD was observed in Bb than in bb 
genotypes (p=0.016) 
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  * Considering the Fok-I genotypes, there was no significant difference in BMD at 
any of the three skeletal sites (p>0.05, ANOVA) both in all the 344 cases and 
among the osteoporotic cases. 
 
3.5.2. Gene × Gene Interaction Effects on BMD: 
   When testing the Cross genotyping effects of the various polymorphisms on 
BMD, the following results were obtained: 
1. Among the Bb individuals, those having the FF genotype had significantly lower 
femoral neck BMD than those having the Ff (p=0.027, ANOVA) or the ff 
(p=0.002, ANOVA) genotypes. Moreover, the BbFF individuals are significantly 
associated with low hip BMD when compared to BbFf individuals (p=0.022, 
ANOVA).  
At the same time, among FF individuals, those having the Bb genotype are 
significantly associated with low hip (p=0.011, ANOVA) and neck (p=0.007, 
ANOVA) BMD than the bb ones . 
2. Among ff individuals, there was a significant decrease in hip BMD for those 
having the BB genotype when compared to Bb genotype (p=0.04, ANOVA). 
3. TT women having the BB genotype are significantly associated with lower hip 
BMD when compared to bb (p=0.005, ANOVA),or Bb (p=0.006, ANOVA) 
women. Moreover, these TTBB women had significantly lower femoral neck 
BMD when compared to TTbb (p=0.02, ANOVA),or TTBb (p=0.01, ANOVA) 
women. 
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4. Among Bb women, those having the CT genotype had significant lower hip 
BMD (P=0.014), and significant lower femoral neck BMD (P=0.005) than those 
having the TT genotype. 
5. FF individuals having the CT genotype are significantly associated with lower 
BMD at both the hip (p=0.033) and femoral neck (p=0.013), than those having the 
TT genotype.  
 
3.5.3. Gene × Nongenetic Interaction Effects on BMD: 
   To investigate whether genotype effects are influenced by other environmental & 
non-environmental factors, the various genotypes were analyzed by grouping 
women according to years since menopause, height, and weight . 
   Since only 3 women (from the total 345) had the CC genotype (table3.1), the 
statistical analysis for the differences in the BMD in the MTHFR gene with 
nongenetic interactions were tested  only between the CT and TT individuals.   
The results of this analysis are described below :- 
 
3.5.3.1. Gene × Years Since Menopause Effects on BMD:  
*Bsm-I × years since menopause: 
    After 15 years of menopause, women having the BB genotype had significant 
lower hip BMD than those having the bb genotype (p=0.045, ANOVA). This 
significant association isn't observed when the years since menopause are < or = 15 
years (p>0.05, ANOVA). 
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*Fok-I × years since menopause: 
     No significant difference in BMD was observed with years since menopause 
between the three Fok-I genotypes at any of the skeletal sites (p>0.05, ANOVA). 
*MTHFR × years since menopause: 
During the first 20 years of menopause, CT women had significant lower BMD at 
the spine (p=0.010), hip (p=0.023), and femoral neck (p=0.017) than TT women. 
On the other hand, after more than 20 years since menopause, no significant 
differences in BMD are observed between these two genotypes (p >0.05). 
3.5.3.2. Gene × Weight Effects on BMD: 
*Bsm-I × weight : 
     Among individuals weighing 80 Kg or more, those having the BB genotype had 
significant lower hip BMD than the bb genotype (p=0.03, ANOVA). This 
significant difference, however, isn't observed in individuals weighing < 80 Kg 
(p>0.05, ANOVA). 
*Fok-I × weight : 
No significant difference in weight-adjusted BMD is observed among the Fok-I  
genotypes at any skeletal site. 
*MTHFR × weight :  
     CT women weighing 70 Kg or more are found to be associated with  significant 
decrease in BMD at both hip (p=0.027) and spine (p=0.041), as compaired to TT 
women having the same weight. However, this decrease in BMD isn't found in CT 
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women weighing less than 70 Kg, and surprisingly in women weighing 90 Kg or 
more. 
3.5.3.3. Gene × Height  Effects on BMD : 
     Women were classified in five groups according to their height. However, 
significant associations appeared at 150 and 160 cm height as follows: 
*Bsm-I × height : 
     Women whose height was 150 cm or more and having the BB genotype, were 
significantly associated with lower hip BMD than did the bb women having the 
same height (p=0.025, ANOVA). Indeed,this significant association disappeared in 
women less than 150 cm height (P>0.05, ANOVA). Moreover, BB women with 
height of 160 cm or more, had significantly lower spinal BMD than did the bb ones 
(p=0.009, ANOVA). 
*Fok-I × height : 
     Short  FF women (< 150 cm height), had significantly lower femoral neck BMD 
than ff women (p=0.031, ANOVA), while those with 150cm or more didn't show 
any effect on BMD (P>0.05, ANOVA). 
*MTHFR × height : 
     Significant differences appeared only in tall women, of 160cm height or more: 
If they had the CT genotype, their BMD was significantly lower at the spine 
(p=0.028),hip (p=0.045),and femoral neck (p=0.011) than those of TT genotype. 
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3.5.3.4. Gene × Height & Weight Effects on BMD : 
  After combining the effects of height and weight together, with the genotypic 
influence, the following interesting results are obtained ( table 3.11):- 
  
 
 
 
 
 
 
 
 
 
 
*Bsm-I × height & weight: 
     The interesting observation is with BB, or Bb tall women whose height is 160 
cm or more . If women weigh 80 Kg or more, their spinal BMD is significantly 
lower than bb women with the same height and weight (p=0.00 for BB, p=0.008 
for Bb, ANOVA). Nothing is observed on BB or Bb tall women (>= 160 cm) 
weighing less than 80 Kg , nor on BB or Bb women less than 160cm height. 
However, very short women (< 150 cm height), weighing less than 80 Kg, also had 
a significant lower BMD at the hip (p=0.033, ANOVA) and femoral neck 
Table 3.11: Gene × Height & Weight Association with BMD:
0.002 for hip
0.044 for spine
0.002 for f.neck
CT<TThip
spine
f.neck
>=90
0.000CT<TTspine>=70
<80
>=160
0.032CT<TTf.neck<60<160MTHFR
Fok-I *
0.034BB<Bbhip>=80
0.033 for hip
0.014 for f.neck
Bb<bbhip, 
f.neck
<80 <150
0.00 for BB
0.008 for Bb
BB , Bb<bbspine>=80>=160Bsm-I
P-valueeffectBMD 
site
Weight
(kg)
Height
(cm)
Polymorphism
* No high significant findings were found, FF(<160 cm, >=70 Kg) < ff (f.neck,p=0.045)
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(p=0.014, ANOVA) if they had the Bb genotype, when compared to bb genotype 
at the same conditions. If they had the BB genotype, however, and their weight 
was 80 Kg or more, their hip BMD was significantly lower than those having the 
Bb genotype of the same height and weight (p=0.034, ANOVA). 
*Fok-I × height & weight : 
     No significant findings were found, except for FF women whose height was 
less than 160 cm: If these women had a weight of 70 Kg or more, they showed a 
significant lower femoral neck BMD than those having the ff genotype (p=0.045, 
ANOVA).Fortunately, FF women with the same height, showed nothing if their 
weight was < 70 Kg (p > 0.05, ANOVA). 
*MTHFR × height & weight : 
     Women less than 160 cm height showed nothing, except when their weight was 
less than 60 Kg: If they had the CT genotype, their femoral neck BMD was 
significantly lower than those having the TT genotype (p=0.032). 
     Unfortunately, CT tall women with 160 cm or more, weighing 70 Kg or more, 
showed many possibilities of very significant lower BMD than TT ones. For 
example:  
-If women are less than 80 Kg ,they were highly associated with lower spinal BMD 
(p=0.000). If they are  90 Kg or more, they're associated with lower BMD at the 
spine (p=0.044), hip (p=0.002), and femoral neck (p=0.002). However, CT short 
women (with height less than 150 cm) showed nothing , except when they weighed 
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90 Kg or more. In this case, a significant lower hip BMD was observed when 
compared to those having the TT genotype (p=0.042). 
   
 
 
 
---------------------------------------------------------------------------------------------------  
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Chapter 4 
Discussion 
 
 
      In recent studies, compelling data from different studies indicate that BMD is – 
at least in part – genetically determined. Morrison and co-workers showed that 
common allelic variants in the gene
 
encoding the vitamin D receptor (VDR) can be
 
used to predict differences in bone densities, claiming
 
that the VDR genetic marker 
accounted for up
 
to 75%
 
of the variation in the heritable component of
 
the peak 
bone mass (Morrison etal. 1992,1994). At the same time, Miyao et al demonstrated 
that the allelic polymorphism in the MTHFR gene was associated with reduced 
BMD in Japanese women (Miyao etal. 2000). Consequently, the hypothesis that 
polymorphisms
 
in the VDR gene and MTHFR gene affect BMD raised
 
great 
interest. Several studies have confirmed the relationship between the VDR or 
MTHFR genotypes and BMD – although some are contradictory – (Tokita 
etal.1996, Salamone etal.1996, Houston etal.1996, Chen etal.2001, Kim etal.2002, 
Jorgensen etal.2002, Bathum etal.2004), while other studies showed negative 
findings (McClure etal.1997, Eccleshall etal.1998, Graafmans etal.1997, Rauch 
etal.1997, Correa etal.1999,… and others). 
      In
 
the present study, we analyzed the Bsm-I
 
and Fok-I
 
polymorphisms of the 
VDR gene, in addition to the MTHFR polymorphism (C677T), and addressed the
 
question of whether there is association between these polymorphisms and BMD in 
the Palestinian population. Furthermore, whether this association is affected by 
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gene-gene interaction, and gene-environmental interaction (including years since 
menopause, height, and weight) was also analyzed. 
* Genotype Distribution: 
      The observed VDR Bsm-I genotype distributions
 
were -to some extent- similar 
to those previously reported by Ferrari and co-workers (Ferrari etal,1995), to those 
reported in the Caucasian (Rizzoli etal,2001), and Danish populations (Tofteng 
etal.2002). In addition,the VDR Fok-I genotype distributions observed in our study 
were nearly in agreement with those reported in the Taiwanese (Chen etal, 2002), 
and American populations (Harris etal,1997). Considering the MTHFR genotypic 
distribution, the majority of the population were heterozygous , some had the TT 
homozygous genotype, while there was a relative lack of the CC genotype . 
* Genotype Association with BMD:   
      Our finding that the BB genotype of the Bsm-I polymorphism was 
significantly associated with  lower BMD at the total hip than the bb genotype  
supports the finding by Langdahl and co-workers (Langdahl etal,2000). Since 
among spinal osteoporotic women, a significant lower BMD was observed in Bb 
than in bb genotypes which means that once a woman has osteoporosis, the 
severity of her bone loss will be great if her genotype is Bb. This also agrees with 
the findings by Kikuchi etal,1999. 
      After adjustment for age since menopause, weight, and height, we found that in 
all cases of BMD significant changes, the "B" allele ( opposing the "b" allele) is 
associated with low BMD. This is consistent with many other studies  including 
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Tokita et al.1996, Sainz et al.1997, Krall et al.1995, Vandevyver et al.1997, 
Viitanen et al.1996, Fleet et al.1995, Geusens et al.1997, Lazaretti-Castro et 
al.1997, Hauache et al.1998, Kikuchi et al.1999, Ferrari et al.1998 and Gomez et 
al.1999. These results – however – contrasts other findings by Salamone et al1996, 
Hauston et al.1996, Tamai et al.1997and Lorentzon et al.2001, where the "B" allele 
was the one associated with high BMD. 
      Concerning years after menopause, our data show that after 15 years of 
menopause, women having the BB genotype had significant lower hip BMD than 
those having the bb genotype. This is in contrast  with those of  Vandevyver etal, 
who showed that the relationship between the Bsm-I VDR
 
gene polymorphism and 
BMD in the elderly, postmenopausal
 
women, is not as strong as shown by
 
others in 
young, premenopausal women (Vandevyver etal, 1997). Evidently, our observation 
is in good agreement with the
 
finding of Krall and co-workers,
 
who observed an 
association between the VDR genotype
 
with baseline femoral neck BMD in late, 
but
 
not in early, menopause, where adjusted femoral neck BMD in the BB group 
was 7%
 
lower than bb and 8%
 
lower than Bb among women in late menopause
 
(
10
 
years). Among women in early menopause (<10
 
years), femoral neck BMD was 
similar in all genotypes (Kral etal,1995). 
      These
 
observations are consistent with the view that genetic
 
factors may have a 
stronger influence on the
 
achievement of the peak bone mass than on
 
the rate of 
bone loss  leading to the 
 
hypothesis that in the elderly other factors  such
 
as age, 
years since menopause, weight, height, Ca
 
intake, vitamin D, and exercise are more 
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important
 
in maintaining the BMD than genetic influences (Vandevyver etal,1997). 
Testing this hypothesis, we studied VDR genotypes in
 
 our subjects, after grouping 
them according to their weight and height, irrespective of their
 
genotypes, 
reflecting the fact that in healthy individuals,
 
weight accounts for most of the
 
interindividual variability in bone mass. Very interesting , it became evident for  
BB, or Bb tall women ,whose height was 160 cm or more, and weigh 80 Kg or 
more, that their spinal BMD was very much significantly lower than bb women of 
the same height and weight. Conversely, nothing was observed on BB or Bb tall 
women weighing less than 80 Kg , nor on BB or Bb women less than 160cm height 
weighing 80 Kg or more. The apparent conclusion from this finding  is that once a 
tall woman knows that her genotype is BB or Bb, she must take care not to 
reach 80 Kg, since this may make her at high risk to develop osteoporosis. 
      The
 
observation that other factors can
  
mask the influence of the VDR 
genotypes on
 
BMD was also shown by Dawson-Hughes and coworkers (Dawson-
Hughes etal,1995).
 
They showed that, compared with women with the
 
bb genotype, 
women with the BB genotype of
 
the VDR gene have reduced calcium absorption 
efficiency
 
on low calcium intake, consistent with a functional
 
defect in the 
intestinal VDR. The impact of
 
this heritable difference is reduced at higher calcium
 
intakes (Vandevyver etal,1997). Furthermore, in another study  done by Kiel & co-
workers , it was concluded  that
 
calcium supplementation was associated with 
greater BMD only
 
for those with the bb genotype. Clearly, the
 
Bsm-I
  
RFLP is in an 
intron of the VDR
 
gene and is not known to alter the
 
protein product ; however, 
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there is early evidence that
 
the rate of VDR gene transcription or stability
 
of the 
transcript may differ according to genotype.
 
While post-transcriptional 
modification related to the Bsm-I
  
RFLP is possible, additional work is needed to
 
identify the mechanism to explain this finding. At present,
 
one likely interpretation 
is that the b allele
 
is in disequilibrium with a mutation within the
 
VDR gene which 
promotes calcium absorption. Further understanding
 
of the biologic mechanisms 
underlying these genetic differences
 
will help define the role of the VDR
 
gene in 
the inheritance of BMD (Kiel etal,1997). 
      Our data concerning the Fok-I RFLP , showed that there was no significant 
difference in BMD at any of the three skeletal sites related directly to any of the 
Fok-I genotypes. This agrees ,to some extent, with the findings done by a number 
of previous studies as Eccleshaa etal.1998, Correa etal.1999, Lucotte etal.1999, 
and Ferrari etal. 1998b, and disagrees with others like Harris etal.1997, Gross 
etal.1996, Aria etal.1997, Ames etal.1999, Lucotte etal.1999,and Gennari etal. 
1999), who observed a trend for lower BMD in the f-allele compared to the F-
allele. Even after adjustment for years after menopause, weight, and height, no 
associations were mentioned , except that considering the height alone (short  FF 
women < 150 cm , had significantly lower femoral neck BMD than ff women), or 
the height and weight together (if  FF women, whose height was less than 160 cm 
had a weight of 70 Kg or more, they showed a significant lower femoral neck 
BMD than those having the ff genotype (p=0.045, ANOVA)). This trend in BMD 
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loss contrasts the trend found in other previous studies, although the p-value 
mentioned here (0.045) isn't  highly significant. 
This guides us to a conclusion that the Fok-I polymorphism isn't very much 
significantly associated with BMD. However, cross-genotyping with other 
polymorphic regions (as mentioned later ) may provide a further insight into the 
complex determination of BMD. 
      Clearly, the Fok-I polymorphism
 
at the translation initiation site in exon 2
 
of 
the VDR gene results in a
 
change in the VDR structure. Since the F-
 
allele lacks the 
first ATG, the mRNA translation
 
would probably initiate from the second ATG 
downstream,
 
thus making the F- allele VDR three amino
 
acids shorter than the f- 
allele VDR. Arai et aI. (1997) have reported that the shorter variant of VDR (F- 
VDR) exhibited greater transcriptional activity in transfected HeLa cells which 
may explain higher BMD in FF individuals. Conversely, Gross et al. (1998) did not 
find functional differences between F-VDR and f-VDR forms. Thus, the molecular 
mechanism of the start codon polymorphism role remains unclear, and the 
differential activity of "F" compared with "f
  
"alleles remains to be proven, but the 
change
 
in VDR amino acid sequence does provide a
 
rational basis from which to 
consider how the
 
VDR SCP polymorphism might affect BMD(Zajickova et al, 
2002). 
      Our results with the MTHFR genotypes, showed that the homozygous TT and 
CC were associated with significantly higher spinal BMD compared to CT . Only 3 
women (from the total 345) had the CC genotype and are normal. However, since 
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the number is too small, we cannot draw any conclusion in association  with the 
CC genotype. Therefore, the statistical analysis for the differences in  BMD with 
the MTHFR gene in association with nongenetic interactions were tested  only 
between the CT and TT individuals. Accordingly, different interesting associations 
became evident : where during early  menopause (not exceeding 20 years), CT 
women had significant lower BMD at the spine, hip, and femoral neck than TT 
women. Considering  weight and height, the risk of developing osteoporosis 
appeared to be great in tall women of 160 cm or more, weighing 70 Kg or more, 
and in short women weighing 90 Kg or more.  
      Clearly, in all MTHFR associations, the TT genotype appeared to be the one 
associated with  higher BMD as compared to the CT genotype. This finding , 
however , is contradictory with the findings by Miyao et al (2000), and 
Abrahamsen et al (2003, 2005) who reported an association between the TT 
genotype and low BMD. It also contradicts the findings of  Bathum et al(2004) and 
Villadsen et al (2004) who reported a significant association between TT genotype 
and increased risk of fracture. Conversely, our results agrees with those of  
Macdonald et al. (2004), where participants with the TT genotype (and high 
riboflavin intake) had higher BMD than the CC and CT groups . Furthermore, our 
findings agrees ,to some extent, with the study done by Jorgensen etal (2002), in 
which they reported a reduced risk of fractures in postmenopausal women 
heterozygous, or homozygous for the T677 polymorphism (although they didn't 
confirm an association with BMD). There is no clear direct explanation for all 
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these discrepancies. However, several factors could be involved. 
First, it is important to note that the studies done by Bathum etal. and Villadsen et 
al. associated the TT genotype with fracture risk, independent of the BMD. Based 
on the biological hypothesis, one could argue that the increased risk of fracture is 
not exclusively mediated through BMD , especially that the effects of the TT 
genotype on fracture risk exceed those expected from BMD alone (Abrahamsen 
etal,2005) , but also reduced bone quality may play a role. The TT genotype is 
associated with elevated levels of circulating homocysteine (p-HCy), and 
homocysteine is known to interfere with the formation of cross-links in collagen, 
an essential process in bone formation. The increased fracture risk could therefore 
be explained by reduced bone strength due to abnormal collagen formation in 
individuals homozygous for the T- allele, alone or in combination with reduced 
BMD (Villadsen etal,2004). Furthermore, Jorgensen et al. proposed the hypothesis 
that the effect of TT genotype on fracture is mediated through factors affecting the 
risk of falling , independent of the BMD values.(Jorgensen etal,2002). 
Second, new studies have drawn attention to a possible role of the vitamin B 
complex in overcoming the effects of MTHFR genotype on the skeleton. 
Specifically, the TT genotype may lead to diminished BMD only in the presence of 
low intake of one or more members of the vitamin B complex. If so, fractures due 
to MTHFR TT genotype could be preventable by vitamin B supplements 
(Abrahamsen etal,2005). Interestingly, recent dietary reports from the Aberdeen 
Osteoporosis Screening Study showed a significant interaction between riboflavin 
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and MTHFR genotype in determining femoral BMD, where participants with the 
TT genotype and high riboflavin intake had higher BMD than the CC and CT 
groups ( Macdonald etal,2004). 
   The total Homocysteine (tHcy) of individuals homozygotic for the T-allele of 
the MTHFR (C677T) mutation is only about 2 to 2.5 μM higher than the normal 
mean fasting level of 10 μM. However, several studies have shown that this 
comparatively small difference in tHcy between the genotypes disappears when the 
intake of folate is high (Jorgensen etal,2002). If the effect on BMD of the MTHFR 
(C677T) genotypes found by Miayao et al. is mediated through the level of tHcy, 
another reason why we got these results could be because of different levels of 
folate intake between Japanese and Palestinian women. 
Third, another possible explanation, is that many of the studied polymorphisms in 
candidate genes have had different allele frequencies in different populations, in 
addition to differences in their effect on BMD and fracture risk. This may be an 
explanation to our results, especially  that the genotype of our studied population is 
89.3% CT , with only 9.9%TT and 0.9% CC. 
 Finally, another possible explanation, is that it isn't the C677T polymorphism in 
the MTHFR gene itself that increases the risk of osteoporosis , but the variants in 
nearby genes on chromosome 1, which are in linkage disequilibrium with this 
polymorphism (Villadsen etal,2004).  
      Interestingly, two recent linkage studies have linked BMD to a region on 
chromosome 1p36, the same region where the MTHFR gene is situated (Devoto 
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etal.2001 , Karasik etal.2002).This furthermore points towards an association 
between the C677T mutation and osteoporosis, although this finding could also be 
due to linkage disequilibrium with other osteoporosis-related gene nearby (Bathum 
etal,2004). 
      It is also very interesting to observe the effect of gene-gene interactions 
between the three polymorphisms on BMD and concluding that  women having the 
haplotypes FFBb, ffBB, BBTT, CTBb, and CTFF were associated with decreased 
hip BMD, while FFBb, BBTT, CTBb, and CTFF women were associated with 
decreased femoral neck BMD. Indeed, this is the first study -worldwide- to cross 
link the VDR polymorphisms with the C677T-MTHFR polymorphism. Therefore, 
these results will provide us with a very important tool to test individuals at an 
early age to identify those with very high risk of osteoporosis based on their 
genetic background, and help them to modify their life style to minimize the risk of 
acquiring the disease and decrease its severity to the minimum. However, It should 
be considered that the functional aspects of the polymorphisms are not clear, and 
because association studies cannot provide any causal evidence between genotype 
and phenotype, functional studies are highly needed (Tofteng etal,2002).   
      In conclusion, this study provides significant associations between the b-allele 
of the Bsm-I VDR and high BMD. It also demonstrates significant associations 
between the CT genotype of the MTHFR with decreased BMD compared to the TT 
genotype. On the contrary, it showes that the Fok-I VDR RFLP alone is a weak 
predictor of BMD, but gene-gene interactions, and  gene environmental 
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interactions gives many significant association results in predicting  BMD.  
Moreover, additional studies linking interactions with other candidate genes ,and 
other environmental factors might bring further insights into the complex 
pathophysiology of a polygenic disease such as osteoporosis. 
---------------------------------------------------------------------------------------------------- 
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